EP1235815A1 - Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes - Google Patents

Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes

Info

Publication number
EP1235815A1
EP1235815A1 EP00976914A EP00976914A EP1235815A1 EP 1235815 A1 EP1235815 A1 EP 1235815A1 EP 00976914 A EP00976914 A EP 00976914A EP 00976914 A EP00976914 A EP 00976914A EP 1235815 A1 EP1235815 A1 EP 1235815A1
Authority
EP
European Patent Office
Prior art keywords
quinazolin
phenyl
cyclopentyl
piperazin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976914A
Other languages
German (de)
French (fr)
Inventor
Mark Robert Barvian
Yadagiri Bathini
Ellen Myra Dobrusin
James Stanley Kaltenbronn
Ronald George Micetich
Inderjit S. Sidhu
Rajeshwar Singh
Peter Laurence Toogood
Roy Thomas Winters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of EP1235815A1 publication Critical patent/EP1235815A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to quinazolines that inhibit cyclin-dependent kinase enzymes, and as such are useful to treat cell proliferative diseases and disorders, such as cardiovascular diseases (i.e., atherosclerosis, restenosis), and cancer, infections (i.e, viral and fungal), autoimmune diseases, organ transplant rejections (i.e., inflammation), gout, kidney disease, and also neurodegenerative diseases and disorders.
  • Cyclin-dependent kinases and related serine/threonine protein kinases are important cellular enzymes that perform essential functions in regulating cell division and proliferation.
  • the cyclin-dependent kinase catalytic units of which 9 have now been described, are activated by regulatory subunits known as cyclins. At least 16 mammalian cyclins have been identified (Johnson D.G. and Walker
  • Cyclin B/Cdkl Cyclin A/Cdk2, Cyclin E/Cdk2, Cyclin D/Cdk4, Cyclin D/Cdk6, and probably other heterodimers including Cdk3 and Cdk7 are important regulators of cell cycle progression. Additional functions of Cyclin/Cdk heterodimers include regulation of transcription, DNA repair, differentiation and apoptosis (Morgan D.O., Annu.
  • Cdk inhibitors also may have potential applications in the treatment of cardiovascular disorders such as restenosis and atherosclerosis.
  • Vascular smooth muscle proliferation and intimal hyperplasia following balloon angioplasty are inhibited by over-expression of the cyclin- dependent kinase inhibitor protein p21 (Chang M. W. et al., J. Clin. Invest., 1995;96:2260; Yang Z-Y. et al., Proc. Natl. Acad. Sci. (USA) 1996;93:9905.
  • Cdk5 The neuronal Cdc2-like kinase, known as Cdk5, together with its brain specific activator protein p35/p25, phosphorylates the neuron-specific microtubule-associated protein tau (Lew J. and Wang J.H., Trends Biochem. Sci. 1995;20:33-37).
  • Aberrant expression of Cdk5 is proposed to contribute to the neurodegenerative disorder Multiple System Atrophy (Nakamura S. et al., J. Neuropathol. Exp. Neurol. 1998;57:690) and tau hyperphosphorylation has long been associated with the pathogenesis of Alzheimer's Disease (AD) (Spillantini M.G. and Giedert M., Trends Neurosci.
  • AD Alzheimer's Disease
  • NFTs neurofibrillary tangles
  • PHF paired helical filament
  • AD Alzheimer's Disease
  • Cdk5 cyclin-dependent kinase 5 (Cdk5), glycogen synthase kinase-3 ⁇ (GSK-3 ⁇ )), and protein phosphatases (type 2 A and 2B)
  • Cdk5 is an important therapeutic target because its activator protein p35 is specifically localized in central and peripheral neurons (Tsai J.-H. et al., Nature 1984;371:419-423).
  • Alzheimer's disease include the following observations. (1) Increased Cdk5 activity has been found in AD brains (Pei J.J. et al., Brain Res. 1998;797:267-77; Lee K.Y. et al., Neurosci Res. 1999;34:21-9). (2) PHF-Tau found in AD brains has 8 phosphorylation sites that overlap with the sites of cdk5 phosphorylation (Paudel H.K. et al., J. Biol. Chem. 1993;268:23512-23518;
  • Cdk inhibitors could find application include those caused by a variety of infectious agents, including DNA and RNA viruses.
  • cyclin-dependent kinases are required for viral replication following infection by herpes simplex virus (HSV) (Schang L.M. et al., J. Virol. 1998;72:5626). HSV replication was inhibited by the cyclin-dependent kinase inhibitors roscovitine and olomoucine but not by a cell cycle inhibitor that does not inhibit cyclin-dependent kinase activity.
  • HSV herpes simplex virus
  • Cdk inhibitor protein pi 6 has both been demonstrated to overcome cell cycle suppression and to promote cell immortalization and the transformed phenotype (Mai A. et al., Nature 1996;380:262-265; Suzuki T. et al., EMBOJ. 1996;15: 1607-1614; Parker G.A. et al., Oncogene 1996;13:2541-2549).
  • Cdk2 also has been implicated in the progression of cytomegalovirus infections (Bresnahan W.A. et al., Virology
  • Fungal infections may be expected to be susceptible to Cdk inhibitors on the basis of the known essential roles of Cdk homologs in yeast.
  • autoimmune disorders may succumb to treatment with selective Cdk inhibitors.
  • the chronic inflammatory disease rheumatoid arthritis is characterized by synovial tissue hyperplasia; inhibition of synovial tissue proliferation should minimize inflammation and prevent joint destruction. Consistent with this idea, expression of the Cdk inhibitor protein pl6 in synovial fibroblasts led to growth inhibition (Taniguchi K. et al., Nat. Med. 1999;5:760-767).
  • joint swelling was substantially inhibited by treatment with a pi 6 expressing adeno virus.
  • Cdk inhibitors may be effective against other disorders of cell proliferation including psoriasis (characterized by keratinocyte hyperproliferation) and possibly lupus. Distinct from gene therapy approaches, many research groups are pursuing small molecule inhibitors of cyclin dependent kinases. Small molecule inhibitors of Cdks that have been published to date include purines such as olomoucine (Vesely et al., Eur. J. Biochem. 1994;224:771-786) and roscovitine (Meijer L. et al., Eur. J. Biochem. 1997;243:527-536), butyrolactone, staurosporine and
  • UCN-01 suramin, 9-hydroxyellipticine, and several flavonoids including flavopiridol (Garrett M.D. and Fattaey A., Curr. Opin. Genes & Develop.
  • Flavopiridol is currently in phase II clinical trials for the treatment of metastatic renal cell carcinoma. It is a relatively nonspecific inhibitor of Cdks and produces cell cycle blocks at Gl and G2. Nonetheless, it is a potent inhibitor of several breast and lung cancer cell lines (Sedlacek H.H. et al., Int. J. Oncol.
  • Cdk inhibitors have been extensively studied in vitro, generally displaying most potency against Cdkl, Cdk2 and Cdk5.
  • Analogs of olomoucine have been synthesized by Meijer and coworkers (Legraverand M. et al., Bioor. Med. Chem. 1999;7:1281-1293 and references therein), Schultz and coworkers (Chang Y-T. et al., Chem. & Biol. 1999;6:361-375), Griffin et al.
  • Cdk inhibitors include aminothiazoles developed independently by Agouron (WO 99/21845) and by Bristol-Myers Squibb (WO 99/24416); indolinones, that have been developed by Sugen (WO 98/50356) and by Glaxo (WO 99/24416); benzothiadiazines (WO 98/49146); peptides (WO 97/11 174); pyrazolo[3,4-b]pyridines (WO 99/30710); and phenylaminopyrimidines (Novartis, unpublished results).
  • Several of these structural classes of protein kinase inhibitors have been reviewed by McMahon et al., Curr. Opin. Drug.
  • This invention provides quinazolines that are useful for treating cell proliferative disorders, such as vascular smooth muscle proliferation associated with atherosclerosis, postsurgical vascular stenosis and restenosis, and endometriosis.
  • This invention also provides quinazolines that are useful for treating infections, including viral infections such as DNA viruses like herpes and RNA viruses like HIV, and fungal infections.
  • This invention further provides quinazolines that are useful for treating autoimmune diseases such as psoriasis, inflammation like rheumatoid arthritis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, and glomerulonephritis, organ transplant rejection, including host versus graft disease.
  • autoimmune diseases such as psoriasis, inflammation like rheumatoid arthritis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, and glomerulonephritis, organ transplant rejection, including host versus graft disease.
  • This invention further provides quinazolines that are useful for treating and neurodegenerative disorders such as Alzheimer's disease.
  • This invention further provides quinazolines that are useful for treating cancer.
  • This invention further provides quinazolines that are useful for treating gout.
  • This invention further provides quinazolines that are useful for treating kidney disease, such as polycystic kidney disease.
  • the above-identified methods of treatment are preferably carried out by administering a therapeutically effective amount of a compound of Formulas I and/or II (set forth below) to a subject in need of treatment.
  • a group of 2-arylamino-7-(alkyl)oxy-8-alkylquinazolines and 8- alkyl-2-arylamino-quinazoline 2,7-diamines are potent inhibitors of cyclin-dependent kinases (cdks).
  • cdks cyclin-dependent kinases
  • the compounds of the invention are members of the class of compounds of Formulas I and II, which will be described further below
  • This invention also provides pharmaceutical formulations comprising a compound of Formulas I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.
  • Compounds within the scope of the present invention are inhibitors of the cyclin-dependent kinases such as cdkl, cdk2, cdk4, and cdk5.
  • cyclin-dependent kinases A new class of compounds have been discovered that are potent inhibitors of cyclin-dependent kinases (cdks) and are useful agents for treating subjects suffering from diseases caused by abnormal cell proliferation.
  • Compounds within the scope of the present invention are inhibitors of the cyclin-dependent kinases such as cdkl, cdk2, cdk4, and cdk5.
  • the compounds of the instant invention are useful in controlling proliferative diseases and disorders, cancer, infections, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders.
  • the compounds of the invention comprise those of Formula I:
  • R 1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl,or heterocycloalkyl;
  • R 2 is OH, alkyloxy, aryloxy, or NR 3 R 4 ;
  • A is N, or CW 3 ;
  • R 3 and R 4 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH 2 ) n Ar, cycloalkyl, heterocycloalkyl, or heteroaryl, or R 3 and R 4 together with the nitrogen to which they are attached optionally may form a ring having 3 to 7 carbon atoms and said ring optionally contains 1 , 2 or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur including S(O) and S(O) 2 .
  • Said ring also may be additionally substituted with up to 3 groups selected from alkyl, haloalkyl, NR 8 C(O)R 9 , C(O)OR 8 , C(O)R 8 , C(O)NR 8 R 9 , NR 8 R 9 , NR 8 SO 2 R 9 , OR 8 , SO,NR 3 R 4 , or SR 8 ;
  • W and W z are independently selected NTDR3 J TR54 4 R ⁇ X, OR 3 , SR 3 , hydrogen, halogen, haloalkyl, COR 3 , CO 2 R 3 , CONR 3 R 4 , S(O)R 3 ,
  • T is
  • R 5 is hydrogen, or alkyl
  • R 6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR 3 , CO 2 R 3 ,
  • OR 3 or NR 3 R 4 W 3 is NR 3 R 4 , N(O)R 3 R 4 , NR 3 R 4 R 8 X, OH, OR 3 , SH, SR 3 , halogen, COR 3 , CO 2 R 3 ,
  • NR 8 C(O)T(CH 2 ) m QR or T(CH 2 ) m CO 2 R 3 where m and n are independently 1-6, T is O, S, NR 3 , N(O)R 3 , NR 3 R 4 W, or CR 3 R 4 , and Q is O, S, NR 9 , N(O)R 9 or NR 9 R 10 X;
  • R 8 , R 9 , R 10 and R 11 are hydrogen, alkyl, or aryl;
  • X is a halogen; or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof.
  • the compounds of the invention further comprise those of Formula II:
  • R 1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl,or heterocycloalkyl;
  • R 2 is OH, alkyloxy, aryloxy, or NR 3 R 4 ;
  • A is N, or CW 3 ;
  • R 3 and R 4 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH 2 ) n Ar, cycloalkyl, heterocycloalkyl, or heteroaryl, or R 3 and R 4 together with the nitrogen to which they are attached optionally may form a ring having 3 to
  • said ring optionally contains 1, 2 or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur including S(O) and S(O) 2 .
  • Said ring also may be additionally substituted with up to 3 groups selected from alkyl, haloalkyl, NR 8 C(O)R 9 , C(O)OR 8 , C(O)R 8 , C(O)NR 8 R 9 , NR 8 R 9 , NR 8 SO 2 R 9 , OR 8 ,
  • W 1 and W 2 are independently selected from NR 3 R 4 , N(O)R 3 R 4 , NR 3 R 4 R 8 X, OR 3 , SR 3 , hydrogen, halogen, haloalkyl, COR 3 , CO 2 R 3 , CONR 3 R 4 , S(O)R 3 , SO 2 R 3 , SO 2 NR 3 R 4 , SO 3 R 3 , P(O)(OR ) 2 , aldehyde, nitrile, nitro, alkyl, T(CH 2 ) m QR 8 , C(O)T(CH 2 ) m QR 8 , or T(CH 2 ) m CO 2 R 8 where m is 1 -6, T is O, S, NR 3 , N(O)R 3 , NR 3 R 4 X, or CR 3 R 4 , and Q is O, S, NR 9 , N(O)R 9 or
  • R 5 is hydrogen, or alkyl
  • R 6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR 3 , CO 2 R 3 , CONR 3 R 4 , SO 2 NR 3 R 4 , SO 2 R 3 , SO 3 R 3 , P(O)(OR ) 2 , aldehyde, nitrile, nitro,
  • OR 3 or NR 3 R 4 W 3 is NR 3 R 4 , N(O)R 3 R 4 , NR 3 R 4 R 8 X, OH, OR 3 , SH, SR 3 , halo, COR 3 , CO 2 R 3 ,
  • NR 3 SO 2 R 4 aldehyde, nitrile, nitro, alkyl, T(CH 2 ) m QR 8 , C(O)T(CH 2 ) m QR 8 , NR 8 C(O)T(CH 2 ) m QR' ' , or T(CH 2 ) m CO 2 R 3 where n and m independently are 1-6; T is O, S, NR 3 , N(O)R 3 , NR 3 R 4 W, or CR 3 R 4 ; and Q is O, S, NR 9 ,
  • R 8 , R 9 , R 10 and R 11 are hydrogen, alkyl, or aryl;
  • X is a halogen; or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof.
  • W 3 include piperidine; piperidine substituted with up to 2 groups consisting of alkyl, haloalkyl, OR 9 , (CH 2 ) n OR 9 , CO 2 R 9 , CONR 9 R 10 , NR 9 R 10 ; 3-aminopyrrolidine, 3-acylaminopyrrolidine; 3- alkylaminopyrrolidine, 3-aminoalkylpyrrolidine; pyrrolidine substituted with up to 3 groups selected from alkyl, haloalkyl, NR 8 C(O)R 9 , C(O)NR 8 R 9 , NR 8 R 9 , OR 8 ; piperazine; N-acylpiperazine; N-aminoacylpiperazine; piperazine substituted with up to five groups selected from alkyl, haloalkyl, OR 8 , (CH 2 ) n OR 8 , CO 2 R 8 , ⁇ R 8 C(O)R 9 , C(O)NR 8 R 9 , NR
  • Especially preferred groups include N-acetylpiperazine, 3,5-dimethylpiperazine, 3,3,4-trimethylpiperazinyl, N-methylpiperazine, homopiperazine, N- acetylhomopiperazine, N-tert-butylacetylpiperazine, N-pivaloylpiperazine, N- leucylpiperazine, N-isoleucylpiperazine; N-valylpiperazine, N-prolylpiperazine,
  • N-alanylpiperazine and N-glycylpiperazine.
  • a preferred group of compounds of Formulas I and II have the above formulas wherein R 1 is alkyl.
  • Another preferred group of compounds of Formulas I and II have the above formulas wherein R 2 is ⁇ R 3 R 4 .
  • Another preferred group of compounds of Formulas I and II have the above formulas wherein A is CW 3 .
  • Another preferred group of compounds of Formulas I and II have the above formulas wherein R 6 is alkyl.
  • Another preferred group of compounds of Formulas I and II have the above formulas wherein Wl, W ⁇ , and W ⁇ are hydrogen.
  • Another preferred group of compounds of Formulas I and II have the above formulas wherein R ⁇ and R > are hydrogen.
  • a particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ , W ⁇ , and W ⁇ are hydrogen, and R! is alkyl.
  • Another particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ , W ⁇ , and W ⁇ are hydrogen, and R! is cycloalkyl.
  • a further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ is piperidine or substituted piperidine, and
  • R! is alkyl or cycloalkyl.
  • a further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ is pyrrolidine or substituted pyrrolidine, and R! is alkyl or cycloalkyl.
  • a further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ is piperazine or substituted piperazine, and R! is alkyl or cycloalkyl.
  • a further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ is piperidine or substituted piperidine, R 2 is alkyloxy, and R! is alkyl or cycloalkyl.
  • a further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ is pyrrolidine or substituted pyrrolidine, R 2 is alkyloxy, and R! is alkyl or cycloalkyl.
  • a further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W ⁇ is piperazine or substituted piperazine, R 2 is alkyloxy, and R! is alkyl or cycloalkyl.
  • Additional preferred embodiments of the present invention include those in Examples 1-10, 85, 54, and 57, infra.
  • Compounds of Formula I wherein R 2 is alkyl, R ⁇ and R > are hydrogen are especially useful as intermediates leading to compounds that display good inhibitory activity against cyclin-dependent kinases.
  • Other especially useful intermediates leading to compounds that display good inhibitory activity against cyclin-dependent kinases are compounds of Formula III
  • Rl, R 2 , R5. and R° are as defined above and X is oxygen or halogen.
  • Particularly useful intermediates are those wherein R 2 is alkyloxy, R ⁇ is hydrogen or alkyl, R 6 is hydrogen, and R° is oxygen or chlorine or a pharmaceutically acceptable salt, ester, amide, or pro-drug thereof.
  • the present invention also discloses processes for preparing compounds of
  • Alkyl means a straight or branched hydrocarbon radical having from
  • 1 to 10 carbon atoms (unless stated otherwise) and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, iso- pentyl, n-hexyl, and the like.
  • Hydro includes fluoro, chloro, bromo, and iodo.
  • Alkenyl means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one double bond and includes ethenyl, 3-buten-l-yl,
  • Alkynyl means straight and branched hydrocarbon radicals having from
  • Cycloalkyl means a monocyclic or polycyclic hydrocarbyl group such as cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, no ⁇ inanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl.
  • groups can be substituted with groups such as hydroxy, keto, and the like.
  • heterocyclyl which means a cycloalkyl group also bearing at least one heteroatom selected from O, S, orNR2, examples being substituted or unsubstituted oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, piperazinyl, acylpiperazinyl, pyrrolidinyl, and mo ⁇ holine.
  • Alkoxy refers to the alkyl groups mentioned above bound through oxygen, examples of which include methoxy, ethoxy, isopropoxy, tert-butoxy, and the like.
  • alkoxy refers to polyethers such as -O-(CH2)2" -CH3, and the like.
  • Alkanoyl groups are alkyl linked through a carbonyl, ie, Ci -C5-C(O)-.
  • Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.
  • acyl means an alkyl or aryl (Ar) group bonded through a carbonyl group, ie, R-C(O)-.
  • acyl includes a Cj-Cg alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by NR4R5 O ⁇ a carboxylic or heterocyclic group.
  • Typical acyl groups include acetyl, benzoyl, and the like.
  • alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted, preferably by 1 to 3 groups selected from NR4R5 ; phenyl, substituted phenyl, thio C j -Cg alkyl, C ⁇ -Cg alkoxy, hydroxy, carboxy, C ⁇ -C5 alkoxycarbonyl, halo, nitrile, cycloalkyl, and a 5- or 6-membered carbocyclic ring or heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, substituted nitrogen, oxygen, and sulfur.
  • "Substituted nitrogen” means nitrogen bearing Cj-Cg alkyl or (CH2) n Ph where n is 1, 2, or 3. Perhalo and polyhalo substitution is also embraced.
  • substituted alkyl groups include 2-aminoethyl, pentachloroethyl, trifluoromethyl, 2-diethylaminoethyl, 2-dimethylaminopropyl, ethoxycarbonylmethyl, 3-phenylbutyl, methanylsulfanylmethyl, methoxymethyl, 3-hydroxypentyl, 2-carboxybutyl, 4-chlorobutyl, 3-cyclopropylpropyl, pentafluoroethyl, 3-mo ⁇ holinopropyl, piperazinylmethyl, and
  • substituted alkynyl groups include 2-methoxyethynyl, 2-ethylsulfanyethynyl, 4-(l-piperazinyl)-3-(butynyl), 3-phenyl-5-hexynyl, 3-diethylamino-3-butynyl, 4-chloro-3-butynyl, 4-cyclobutyl-4-hexenyl, and the like.
  • Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, 3-hydroxypropoxy, 6-carboxhexyloxy, and the like.
  • substituted alkyl, alkenyl, and alkynyl groups include dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-l-yl,
  • heteroaryl refers to unsubstituted and substituted aromatic groups.
  • Heteroaryl groups have from 4 to 9 ring atoms, from 1 to 4 of which are independently selected from the group consisting of O, S, and N.
  • Preferred heteroaryl groups have 1 or 2 heteroatoms in a 5- or 6-membered aromatic ring.
  • Mono and bicyclic aromatic ring systems are included in the definition of aryl and heteroaryl.
  • Typical aryl and heteroaryl groups include phenyl, 3-chlorophenyl, 2,6-dibromophenyl, pyridyl, 3-methylpyridyl, benzothienyl, 2,4,6-tribromophenyl, 4-ethylbenzothienyl, furanyl, 3,4-diethylfuranyl, naphthyl, 4,7-dichloronaphthyl, pyrrole, pyrazole, imidazole, thiazole, and the like.
  • Preferred Ar groups are phenyl and phenyl substituted by 1, 2, or 3 groups independently selected from the group consisting of alkyl, alkoxy, thio, thioalkyl, hydroxy, -COOR 7 , amino of the formula -NR 4 R 5 , and T(CH2) m QR 4 or T(CH 2 ) m CO 2 R 4 wherein m is 1 to 6, T is O, S, NR 4 , N(O)R 4 , NR 4 R 6 Y, or
  • CR 4 R 5 , Q is O, S, NR 5 , N(O)R 5 , or NR 5 R6 ⁇ wherein R 4 and R 5 are as described above, and R 7 is alkyl or substituted alkyl, for example, methyl, trichloroethyl, diphenylmethyl, and the like.
  • R 7 is alkyl or substituted alkyl, for example, methyl, trichloroethyl, diphenylmethyl, and the like.
  • the alkyl and alkoxy groups can be substituted as defined above.
  • typical groups are carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, hydroxyalkoxy, and alkoxyalkyl.
  • patient means all animals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, and pigs.
  • the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.
  • the solvated forms, including hydrated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
  • the compounds of Formulas I, II, and III are capable of further forming both pharmaceutically acceptable formulations comprising salts, esters, amides, and prodrugs.
  • pharmaceutically acceptable salts, esters, amides, and prodrugs refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed and including, but not limited to, acid addition and/or base salts, solvents and N-oxides of a compound of Formulas I, II, and III.
  • This invention also provides pharmaceutical formulations comprising a compound of Formulas I, II, or III together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. All of these forms are within the present invention.
  • Formulas I, II and III include salts derived form inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like
  • organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
  • salts of amino acids such as arginate, gluconate, galacturonate, and the like; see, for example, Berge, et al., "Pharmaceutical Salts,” J. of Pharmaceutical Science, 1977;66:1-19.
  • the acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
  • the free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner.
  • the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for pu ⁇ oses of the present invention.
  • Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like.
  • Suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine; see, for example, Berge, et al., supra.
  • the base addition salts of acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
  • the free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner.
  • the free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for pu ⁇ oses of the present invention.
  • esters of the compounds of this invention examples include Cj-Cgalkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include Cf-C cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C]-C4alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
  • Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary
  • the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom.
  • Amides derived from ammonia, Ci -C alkyl primary amines, and Ci -C2dialkyl secondary amines are preferred.
  • Amides of the compounds of the invention may be prepared according to conventional methods.
  • the term "pro-drug” refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American
  • a therapeutically effective amount is an amount of a compound of Formulas I, II, or III, that when administered to a patient, ameliorates a symptom of the disease.
  • cardiovascular disorders and diseases includes, but is not limited to atherosclerosis, psoriasis, and restenosis.
  • Those skilled in the art are easily able to identify patients having atherosclerosis, psoriasis, restenosis, or at risk of having atherosclerosis or restenosis.
  • patients who are at risk of having restenosis include, but are not limited to, patients having undergone balloon angioplasty or other surgical vascular procedures.
  • cancer includes, but is not limited to, the following cancers: breast; ovary; cervix; prostate; testis; esophagus; glioblastoma; neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoid carcinoma, large cell carcinoma, adenocarcinoma; bone; colon, adenocarcinoma, adenoma; pancreas, adenocarcinoma; thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladder carcinoma; liver carcinoma and biliary passages; kidney carcinoma; myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine; colon-rectum, large intestine, rectum; brain and central nervous system; and leukemia.
  • autoimmune disease includes, but is not limited to inflammation, such as rheumatoid arthritis, and organ graft rejections.
  • kidney disease includes, but is not limited to kidney disease, such as polycystic kidney disease.
  • Compounds within the scope of the present invention effectively inhibit vascular smooth muscle cell proliferation and migration.
  • the method entails inhibiting vascular smooth muscle proliferation, and/or migration by administering an effective amount of a compound of Formulas I, II, or III to a subject in need of treatment.
  • the compounds of the present invention are useful for treating cancer (for example, leukemia and cancer of the lung, breast, prostate, and skin such as melanoma), cardiovascular disorders and diseases, infections, autoimmune diseases, gout, kidney diseases, and neurodegenerative diseases and disorders.
  • cancer for example, leukemia and cancer of the lung, breast, prostate, and skin such as melanoma
  • cardiovascular disorders and diseases infections, autoimmune diseases, gout, kidney diseases, and neurodegenerative diseases and disorders.
  • a patient having the indication is administered a therapeutically effective amount of a pharmaceutically acceptable composition comprising an invention compound.
  • the term "neurological disease and disorders" includes, but is not limited to, Alzheimer's disease.
  • Compounds within the scope of the present invention effectively inhibit the degradation of neurons.
  • the method entails inhibiting neural degeneration by administering an effective amount of a compound of Formulas I, II, or III to a subject in need of treatment.
  • the compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms, including transdermal and rectal administration. It will be recognized to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formulas I, II, or III or a corresponding pharmaceutically acceptable salt or solvate of a compound of Formulas I, II, or III.
  • a further embodiment of this invention is a pharmaceutical formulation comprising a compound of Formulas I, II, or III together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.
  • pharmacuetically acceptable carriers can be either a solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid such as talc or starch which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the formulations of this invention preferably contain from about 5% to about 70% or more of the active compound.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • capsules which include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • a carrier which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogenously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient size molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions such as water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution, isotonic saline, 5% aqueous glucose, and the like.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water and mixing with a viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
  • a viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • Such liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. Waxes, polymers, microparticles ⁇ and the like can be utilized to prepare sustained-release dosage forms.
  • osmotic pumps can be employed to deliver the active compound uniformally over a prolonged period.
  • the pharmaceutical preparations of the invention are preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the therapeutically effective dose of a compound of Formulas I, II, or III will generally be from about 1 mg to about 100 mg/kg of body weight per day. Typical adult doses will be about 50 mg to about 800 mg per day.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from about 0.1 mg to about 500 mg, preferably about 0.5 mg to 100 mg according to the particular application and the potency of the active component.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • a subject in need of treatment with a compound of Formulas I, II, or III is administered a dosage of about 1 to about 500 mg per day, either singly or in multiple doses over a 24-hour period.
  • the compounds of the present invention are capable of binding to and inhibiting the activity of proteins having the ability to phosphorylate other proteins, such as cdks. Cdks form complexes with cyclins, and these complexes phosphorylate key proteins allowing cells to proceed through the cell cycle (Meijer L., Progress in Cell Cycle Research, 1995;1 :351-363).
  • the compounds of this invention inhibit this phosphorylation and therefore can be used as anti- proliferative agents for the treatment of cancer and/or restenosis and other proliferative diseases, and as anti-neural degenerative agents for the treatment of neural degenerative disorders such as Alzheimer's disease.
  • the compounds of the present invention are also useful research tools for studying the mechanism of action of those kinases, both in vitro and in vivo. While the forms of the invention herein constitute presently preferred embodiments, many others are possible. It is not intended herein to mention all of the possible equivalent forms or ramifications of the invention. It is understood that the terms used herein are merely descriptive rather than limiting, and those skilled in the art will realize that various changes may be made without departing from the spirit or scope of the invention.
  • Scheme 1 describes a typical method for the preparation of the quinazoline compounds of the invention.
  • BocN ⁇ NHBoc (ref Bernatowivz et al
  • EXAMPLE 5 6-Hydroxymethylene-2-isopropyl-3-methoxy-cyclohex-2-enone To a suspension of sodium hydride (3.6 g, 60% suspension, 90 mmol) in benzene (100 mL), a mixture of ethyl formate (12.5 g) and 2-isopropyl-3 -methoxy- cyclohex-2-enone (5 g, 29.7 mmol) in benzene was added dropwise at 5°C. The reaction mixture was stirred at ice temperature for 1 hour, and at room temperature for 18 hours. The reaction mixture was cooled in an ice bath, and 10%) sodium hydrogen phosphate solution (200 mL) was added dropwise.
  • EXAMPLE 6 8-Isopropyl-7-methoxy-quinazolin-2-ylamine A mixture of 6-hydroxymethylene-2-isopropyl-3-methoxy-cyclohex-2-enone (3.5 g) and guanidine carbonate (7 g) in DMF (40 mL) was heated at 150°C for
  • the dihydroquinazoline was aromatized to the title compound by heating in nitrobenzene at 150°C in the ' presence of 10%> Pd-C.
  • nitrobenzene 20 mL
  • 200 mg of 10% Pd-C was added, and the reaction mixture was heated at 150°C for 3 days.
  • the Pd-C was removed by filtration.
  • the filtrate was concentrated, and the resulting product was purified on a column of silica gel (Hex:EtOAc) to give the title compound as an off-white solid (1 g, 50% yield), mp
  • the compounds of this invention are potent inhibitors of cyclin-dependent kinases, and accordingly, are useful in treating and preventing neurodegenerative disorders, atherosclerosis, and other cell proliferative disorders like cancer.
  • the compounds have exhibited excellent inhibitory activity against a wide variety of cyclin-dependent kinases, all in assay systems routinely utilized to measure such activity.
  • a typical assay measures inhibitory activity against the cyclin D dependent kinase 4 enzyme (cdk4/D).
  • the invention compounds of Formula I exhibited IC50 values ranging generally from 0.011 ⁇ iM to 1.75 ⁇ M.
  • the cdk4 assay was carried out as follows. Cyclin-Dependent Kinase 4 (cdk4) Assay
  • Enzyme assays for IC50 determinations (Table 1 above) and kinetic evaluation were performed in 96 well filter plates (Millipore MADVN6550). The total volume was 0.1 mL containing a final concentration of 20 mM TRIS (tris[hydroxymethyl]aminomethane), at pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 ⁇ M ATP containing 0.25 ⁇ Ci of [ 32 P]ATP,
  • cdk4 20 ng of cdk4, 1 ⁇ g of retinoblastoma, and appropriate dilutions of a compound of the present invention. All components except the ATP were added to the wells, and the plate was placed on a plate mixer for 2 minutes. The reaction was started by adding [32p]ATP and the plate was incubated at 25 °C for 15 minutes. The reaction was terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate was kept at 4°C for at least 1 hour to allow the substrate to precipitate.
  • TCA trichloroacetic acid
  • IC50 values were determined using enzyme assays performed in a total volume of 0.1 mL of a solution comprising 25 mM Hepes, pH 7.4, 5 mM MgCL2, 2 mM MnCL2, 50 ⁇ M sodium vanadate, 5 to 10 ng of cdk4, and 200 ⁇ M of a substrate peptide Ala-Glu-Gly-Ser-Ala-Tyr472.Qiu.Qiu_Yai.NH2, derived from the amino acid [Try4 ' h as Deen shown to be 1 of 4 tyrosines in PLC- ⁇ that are phosphorylated by the EGF receptor tyrosine kinase (Wahl M.I., et al., J Biol.
  • the reaction was terminated by the addition of 2 mL of 75 mM phosphoric acid, and the contents of the reaction passed through a 2.5 cm phosphocellulose filter disc to bind the peptide.
  • the filter was washed five times with 75 mM phosphoric acid, placed in a vial along with 5 mL of scintillation fluid (Ready gel, Beckman), and counted on a scintillation counter.
  • the compounds of Formula I have also exhibited good inhibitor activity against other cyclin-dependent kinase enzymes such as cdk2/cyclinE, cdk2/cyclinA, and cdk 1 /cyclinB .
  • the invention compounds When measured against cdk2/E. the invention compounds exhibited IC50 values ranging generally from about 0.004 to greater than 5 ⁇ M. Against cdk2/A, the compounds exhibited IC50 values ranging from about 0.028 to greater than
  • Source of enzyme recombinant baculovirus-infected insect cell sf9 - expressed recombinant Cdk5-p25 complex
  • Pu ⁇ ose To evaluate the ability of test agents to inhibit Cdk5/p25 phosphorylation of Histone HI.
  • Method Baculovirus-insect cell His-tagged Cdk5/Glu-tagged p25 (or GST-p25) enzyme complex is diluted to a concentration of 50 ng/20 ⁇ L in Enzyme Dilution Buffer (EDB - 50 mM Tris-HCl [pH 8.0], 10 mM NaCl, 10 mM MgCl , and
  • test agent 1 mM DTT
  • 20 ⁇ L sample of test agent diluted in EDB
  • 20 ⁇ L of the of the final Cdk5/p25 enzyme preparation is then combined with 20 ⁇ L of the of the final Cdk5/p25 enzyme preparation and allowed to stand for 5 minutes at room temperature.
  • Twenty-five microliters of substrate solution containing 115 ⁇ L/mL Histone HI, 30 ⁇ M ATP (vanadate-free), and 30 ⁇ iCi/mL ⁇ .33p ATP (Amersham) in EDB is then added to the test agent/enzyme preparation and shaken at 30°C for 45 minutes.
  • a 50 ⁇ L sample of the final preparation is added to 100 mL of 150 mM phosphoric acid on ice for 30 minutes to facilitate precipitation.
  • the precipitate is then filtered through a 96 well phosphocellucose filter plate and subsequently rinsed 3 times with 75 mM phosphoric acid. Each well then receives 20 ⁇ L of scintillation cocktail, and the plates are counted for beta emissions using a Trilux Counter ( 33 p filter protocol). Test samples are compared to Control (no test agent present; as 0% inhibition) and
  • Baseline level no enzyme, no test agent; as 100% inhibition beta emissions to determine the percent inhibition of Histone HI phosphorylation.
  • the invention compounds can be formulated in conventional manners to provide convenient dosage forms for delivery to mammals by various routes, including oral, parenteral (i.e., subcutaneous, intravenous, and intramuscular), transdermal, e.g. slow release skin patch or cream, as well as by slow release delivery devices such as osmotic pumps, suppositories, and buccal seals.
  • parenteral i.e., subcutaneous, intravenous, and intramuscular
  • transdermal e.g. slow release skin patch or cream
  • slow release delivery devices such as osmotic pumps, suppositories, and buccal seals.
  • magnesium stearate (1 20 g
  • the quinazoline, lactose, and corn starch (for mix) are blended to uniformity.
  • the corn starch (for paste) is suspended in 600 mL of water and heated with stirring to form a paste. This paste is used to granulate the mixed powders.
  • the wet granules are passed through a No. 8 hand screen and dried at 80°C.
  • the dry granules are then passed through a No. 16 screen.
  • the mixture is lubricated with 1 % magnesium stearate and compressed into tablets in a conventional tableting machine.
  • the tablets are useful for treating cancers such as breast, prostate, lung, ovarian, colon, pancreatic, melanoma, esophageal, brain,
  • Kaposi's sarcoma and lymphomas, or neurodegenerative disorders such as Alzheimer's.
  • Example 20 In a solution of 700 mL of propylene glycol and 200 mL of water for injection is suspended 20.0 g of Example 20 with stirring. After suspension is complete, the pH is adjusted to 5.5 with hydrochloric acid, and the volume is made up to 1000 mL with water for injection. The formulation is sterilized, filled into 5.0 mL ampoules, each containing 2.0 mL (representing 40 mg of invention compound) and sealed under nitrogen.
  • EXAMPLE 54 Suppositories A mixture of 400 mg of Example 20, and 600 mg of theobroma oil is stirred at 60°C to uniformity. The mixture is cooled and allowed to harden in a tapered mold to provide a 1 g suppository.
  • Example 55 Slow Release Formulation Five hundred milligrams of Example 20 is converted to a hydrochloride salt and placed into an Oros osmotic pump for controlled release for treatment of atherosclerosis.
  • Example 56 Skin Patch Formulation Fifty milligrams of Example 20 is admixed with 50 mg of propylene glycol monolaurate in a polydimethylsiloxane adhesive. The mixture is layered onto an elastic film made with an adhesive formulation of polybutene, polyisobutylene, and propylene glycol monolaurate. The layers are placed between 2 layers of polyurethane film. A release liner is attached to the adhesive surface, and is removed prior to application to a skin surface. The propylene glycol monolaurate serves as a permeation-enhancing agent.

Abstract

This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provides useful intermediates generated during the production of the quinazoline compounds.

Description

QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-
DEPENDENT KINASE ENZYMES
FIELD OF THE INVENTION
This invention relates to quinazolines that inhibit cyclin-dependent kinase enzymes, and as such are useful to treat cell proliferative diseases and disorders, such as cardiovascular diseases (i.e., atherosclerosis, restenosis), and cancer, infections (i.e, viral and fungal), autoimmune diseases, organ transplant rejections (i.e., inflammation), gout, kidney disease, and also neurodegenerative diseases and disorders.
SUMMARY OF THE RELATED ART
Cyclin-dependent kinases and related serine/threonine protein kinases are important cellular enzymes that perform essential functions in regulating cell division and proliferation. The cyclin-dependent kinase catalytic units, of which 9 have now been described, are activated by regulatory subunits known as cyclins. At least 16 mammalian cyclins have been identified (Johnson D.G. and Walker
C.L., Annu. Rev. Pharmacol. Toxicol. 1999;39:295-312). Cyclin B/Cdkl, Cyclin A/Cdk2, Cyclin E/Cdk2, Cyclin D/Cdk4, Cyclin D/Cdk6, and probably other heterodimers including Cdk3 and Cdk7 are important regulators of cell cycle progression. Additional functions of Cyclin/Cdk heterodimers include regulation of transcription, DNA repair, differentiation and apoptosis (Morgan D.O., Annu.
Rev. Cell. Dev. Biol. 1997;1361-191).
Increased activity or temporally abnormal activation of cyclin-dependent kinases has been shown to result in the development of human tumors (Sherr C.J., Science 1996;274:1672-1677). Indeed, human tumor development is commonly associated with alterations in either the Cdk proteins themselves or their regulators
(Cordon-Cardo C, Am. J. Pathol. 1995;147:545-560; Karp J. E. and Broder S., Nat. Med. 1995;1 :309-320; Hall M. et al., Adv. Cancer Res. 1996;68:67-108). These and other observations have prompted an intensive search for small molecule Cdk inhibitors. Strong validation for this approach is provided by studies of naturally occurring protein inhibitors of Cdks (Kamb A., Curr. Top. Microbiol. Immunol. 1998;227:139-148). Introduction of pl6 into lung cancer cell lines blocked entry into S phase and caused growth inhibition (Jin X. et al., Cancer Res. 1995;55:3250-3253; Chintaia S.K. et al, Oncogene 1997;15:2049-2057). Other studies demonstrated a similar effect for p27 (Craig C. et al., Oncogene 1997;14:2283-2289). Ectopic expression of the Cdk inhibitors p21 or p27 in U937 human leukemia cells resulted in growth arrest and cellular differentiation (Liu et al., Genes Dev., 1996;10:142-153). Markers of differentiation also were observed in the non-small lung cancer cell line NCI-H358 following expression of antisense
Cdk2. Expression of antisense cyclin Dl in human esophageal cancer cells resulted in growth inhibition (Zhou P. et al., Oncogene, 1995;11 :571-580).
Further support for targeting Cdk2 with therapeutic agents is found in the work of Chen et al., Proc. Natl. Acad. Sci. (USA) 1999;96:4325-4329, who demonstrated selective killing of transformed U2OS cells containing deregulated
E2F using peptide inhibitors of Cyclin A/Cdk2. Untransformed cell lines were unaffected by these inhibitors. Thus, Cdk inhibitors potentially could demonstrate efficacy in vivo with a useful margin of safety.
In addition to treating cancer, Cdk inhibitors also may have potential applications in the treatment of cardiovascular disorders such as restenosis and atherosclerosis. Vascular smooth muscle proliferation and intimal hyperplasia following balloon angioplasty are inhibited by over-expression of the cyclin- dependent kinase inhibitor protein p21 (Chang M. W. et al., J. Clin. Invest., 1995;96:2260; Yang Z-Y. et al., Proc. Natl. Acad. Sci. (USA) 1996;93:9905. Moreover, intraluminal exposure of a denuded rat carotid artery to the purine
Cdk2 inhibitor CVT-313 (Ki = 95 nM) resulted in greater than 80% inhibition of neointima formation (Brooks E.E. et al., J. Biol. Chem. 1997:29207-29211). Taken together, these observations support the use of small molecule inhibitors of cell cycle progression in the treatment of vascular disorders that are due to aberrant cell proliferation.
The neuronal Cdc2-like kinase, known as Cdk5, together with its brain specific activator protein p35/p25, phosphorylates the neuron-specific microtubule-associated protein tau (Lew J. and Wang J.H., Trends Biochem. Sci. 1995;20:33-37). Aberrant expression of Cdk5 is proposed to contribute to the neurodegenerative disorder Multiple System Atrophy (Nakamura S. et al., J. Neuropathol. Exp. Neurol. 1998;57:690) and tau hyperphosphorylation has long been associated with the pathogenesis of Alzheimer's Disease (AD) (Spillantini M.G. and Giedert M., Trends Neurosci. 1998;21 :428-433). In addition to amyloid plaques, neurofibrillary tangles (NFTs) are a primary marker for AD. The major component of NFTs are paired helical filament (PHF)-tau, which is a filamentous aggregate of hyperphosphorylated tau. The "NFT load" in the brains of Alzheimer's Disease (AD) patients is strongly correlated with severity of the disease. This correlation is stronger than that seen for Aβ-rich amyloid plaques.
Abnormal activation of protein kinases (cyclin-dependent kinase 5 (Cdk5), glycogen synthase kinase-3β (GSK-3β)), and protein phosphatases (type 2 A and 2B), has been implicated in tau hyperphosphorylation and pathological activation of Cdk5 is likely a major contributor to PHF-tau. Cdk5 is an important therapeutic target because its activator protein p35 is specifically localized in central and peripheral neurons (Tsai J.-H. et al., Nature 1984;371:419-423). Indeed the abnormal deposition of amyloid beta peptide (from the APP gene) and hyperphosphorylated tau may be combined factors that lead to early onset AD (Mandelkow E.-M. and Mandelkow E., Trends Cell Biol. 1998;8:425-427). There is growing evidence that abnormally processed tau also is associated with other CNS diseases. Recently, mutations in the tau gene on chromosome 14 have been linked to fronto-temporal dementia with Parkinsonism (FTDP-17) and progressive supernuclear palsy (PSP) (Spillantini M.G. and Giedert M., Trends Neurosci. 1998;21 :428-433). Further evidence supporting the role of Cdk5 in tauopathy and
Alzheimer's disease include the following observations. (1) Increased Cdk5 activity has been found in AD brains (Pei J.J. et al., Brain Res. 1998;797:267-77; Lee K.Y. et al., Neurosci Res. 1999;34:21-9). (2) PHF-Tau found in AD brains has 8 phosphorylation sites that overlap with the sites of cdk5 phosphorylation (Paudel H.K. et al., J. Biol. Chem. 1993;268:23512-23518;
Baumann K. et al., FEBS Lett. 1993;336:417-424). (3) Synergy among the different tau protein kinases eg, Cdk5-phosphorylated tau is more readily phosphorylated by GSK3 (Sengupta A., et al., Mol. Cell. Biochem. 1997; 167:99-105).
Other diseases in which Cdk inhibitors could find application include those caused by a variety of infectious agents, including DNA and RNA viruses. For example, cyclin-dependent kinases are required for viral replication following infection by herpes simplex virus (HSV) (Schang L.M. et al., J. Virol. 1998;72:5626). HSV replication was inhibited by the cyclin-dependent kinase inhibitors roscovitine and olomoucine but not by a cell cycle inhibitor that does not inhibit cyclin-dependent kinase activity. Inactivation of the Cdk inhibitor protein pi 6 by the viral protein Tax, and inactivation of p27 by viral El A, have both been demonstrated to overcome cell cycle suppression and to promote cell immortalization and the transformed phenotype (Mai A. et al., Nature 1996;380:262-265; Suzuki T. et al., EMBOJ. 1996;15: 1607-1614; Parker G.A. et al., Oncogene 1996;13:2541-2549). Cdk2 also has been implicated in the progression of cytomegalovirus infections (Bresnahan W.A. et al., Virology
1997;231 :239-247; Albrecht T. et al., WO 98/39007). Fungal infections may be expected to be susceptible to Cdk inhibitors on the basis of the known essential roles of Cdk homologs in yeast.
It is further possible that various autoimmune disorders may succumb to treatment with selective Cdk inhibitors. The chronic inflammatory disease rheumatoid arthritis is characterized by synovial tissue hyperplasia; inhibition of synovial tissue proliferation should minimize inflammation and prevent joint destruction. Consistent with this idea, expression of the Cdk inhibitor protein pl6 in synovial fibroblasts led to growth inhibition (Taniguchi K. et al., Nat. Med. 1999;5:760-767). Similarly, in a rat model of arthritis, joint swelling was substantially inhibited by treatment with a pi 6 expressing adeno virus. By extension, Cdk inhibitors may be effective against other disorders of cell proliferation including psoriasis (characterized by keratinocyte hyperproliferation) and possibly lupus. Distinct from gene therapy approaches, many research groups are pursuing small molecule inhibitors of cyclin dependent kinases. Small molecule inhibitors of Cdks that have been published to date include purines such as olomoucine (Vesely et al., Eur. J. Biochem. 1994;224:771-786) and roscovitine (Meijer L. et al., Eur. J. Biochem. 1997;243:527-536), butyrolactone, staurosporine and
UCN-01, suramin, 9-hydroxyellipticine, and several flavonoids including flavopiridol (Garrett M.D. and Fattaey A., Curr. Opin. Genes & Develop.
1999;9:104-111; Walker D.H., Curr. Top. Microbio. Immunol. 1998:148-165; Meijer L., Meths. In Enzymol. 1997;223:113-128). Of these inhibitors, most information is available for flavopiridol.
Flavopiridol is currently in phase II clinical trials for the treatment of metastatic renal cell carcinoma. It is a relatively nonspecific inhibitor of Cdks and produces cell cycle blocks at Gl and G2. Nonetheless, it is a potent inhibitor of several breast and lung cancer cell lines (Sedlacek H.H. et al., Int. J. Oncol.
1996:1143-1168; Kaur et al., J Natl. Cancer Inst. 1992;84:1736-1740; Bible K.C. and Kaufman S.H., Cancer Res. 1996;56:4856-4861) and displays growth inhibitory activity against tumors in vivo (Patel V. et al., J. Clin. Invest.
1998;102:1674-1681; Drees M. et al., Clin. Cancer Res. 1997;3:273-279; Wright J. et al., Oncology 1998;12: 1018, 1023-1014; Senderowicz A.M. et al.,
J Clin. Oncol. 1998; 16 2988-2999). Flavopiridol analogs have been described by
Mitotix (International patent application WO 97/16447; US Patent 5,733,920) as well as by Bristol-Myers Squibb (WO 97/42949).
The purine class of Cdk inhibitors have been extensively studied in vitro, generally displaying most potency against Cdkl, Cdk2 and Cdk5. Analogs of olomoucine have been synthesized by Meijer and coworkers (Legraverand M. et al., Bioor. Med. Chem. 1999;7:1281-1293 and references therein), Schultz and coworkers (Chang Y-T. et al., Chem. & Biol. 1999;6:361-375), Griffin et al.
(International patent application WO 99/02162) and Mackman et al., (US Patent 5,866,702; WO 98/05335), among others. One of these compounds has been shown to inhibit neointimal formation in an animal model of restenosis (see above).
Other classes of small molecule Cdk inhibitors described in the patent literature include aminothiazoles developed independently by Agouron (WO 99/21845) and by Bristol-Myers Squibb (WO 99/24416); indolinones, that have been developed by Sugen (WO 98/50356) and by Glaxo (WO 99/24416); benzothiadiazines (WO 98/49146); peptides (WO 97/11 174); pyrazolo[3,4-b]pyridines (WO 99/30710); and phenylaminopyrimidines (Novartis, unpublished results). Several of these structural classes of protein kinase inhibitors have been reviewed by McMahon et al., Curr. Opin. Drug. Discovery & Develop. 1998;1 :131-146). Very little in vitro data and no clinical data are available for any of these compounds, and there is still a need for more potent and selective Cdk inhibitors with good pharmacokinetic properties that can be employed not just as in vitro tools but also in vivo.
We have previously described a class of pyrido[2,3d]pyrimidines that display selectivity for Cdks versus other protein kinases (WO 98/33798). These compounds are distinct from the 6-aryl-pyrido[2,3d]pyrimidines (WO 96/15128; WO 96/34867) which display the opposite selectivity, preferring tyrosine kinases over cyclin-dependent kinases. Moreover, they represent a new structural class when compared to either the pyrimidines and 3,4-dihydropyrimidines of International Patent application, PCT/US99/10187, filed May 10, 1999, or the naphthyridones described in international patent application WO 99/09030. Despite the progress that has been made, the search continues for small molecular weight compounds that are orally bioavailable and useful for treating a wide variety of cell proliferative diseases and disorders, cancer, infections, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders.
SUMMARY OF THE INVENTION
This invention provides quinazolines that are useful for treating cell proliferative disorders, such as vascular smooth muscle proliferation associated with atherosclerosis, postsurgical vascular stenosis and restenosis, and endometriosis. This invention also provides quinazolines that are useful for treating infections, including viral infections such as DNA viruses like herpes and RNA viruses like HIV, and fungal infections.
This invention further provides quinazolines that are useful for treating autoimmune diseases such as psoriasis, inflammation like rheumatoid arthritis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, and glomerulonephritis, organ transplant rejection, including host versus graft disease.
This invention further provides quinazolines that are useful for treating and neurodegenerative disorders such as Alzheimer's disease. This invention further provides quinazolines that are useful for treating cancer.
This invention further provides quinazolines that are useful for treating gout.
This invention further provides quinazolines that are useful for treating kidney disease, such as polycystic kidney disease.
The above-identified methods of treatment are preferably carried out by administering a therapeutically effective amount of a compound of Formulas I and/or II (set forth below) to a subject in need of treatment. It has been discovered that a group of 2-arylamino-7-(alkyl)oxy-8-alkylquinazolines and 8- alkyl-2-arylamino-quinazoline 2,7-diamines are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally and parenterally, and have little or no toxicity. The compounds of the invention are members of the class of compounds of Formulas I and II, which will be described further below This invention also provides pharmaceutical formulations comprising a compound of Formulas I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.
Compounds within the scope of the present invention are inhibitors of the cyclin-dependent kinases such as cdkl, cdk2, cdk4, and cdk5.
DETAILED DESCRIPTION OF THE INVENTION
A new class of compounds have been discovered that are potent inhibitors of cyclin-dependent kinases (cdks) and are useful agents for treating subjects suffering from diseases caused by abnormal cell proliferation. Compounds within the scope of the present invention are inhibitors of the cyclin-dependent kinases such as cdkl, cdk2, cdk4, and cdk5. As inhibitors of cyclin-dependent kinases, the compounds of the instant invention are useful in controlling proliferative diseases and disorders, cancer, infections, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders.
The compounds of the invention comprise those of Formula I:
wherein,
R1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl,or heterocycloalkyl;
R2 is OH, alkyloxy, aryloxy, or NR3R4;
A is N, or CW3;
R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH2)nAr, cycloalkyl, heterocycloalkyl, or heteroaryl, or R3 and R4 together with the nitrogen to which they are attached optionally may form a ring having 3 to 7 carbon atoms and said ring optionally contains 1 , 2 or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur including S(O) and S(O)2. Said ring also may be additionally substituted with up to 3 groups selected from alkyl, haloalkyl, NR8C(O)R9, C(O)OR8, C(O)R8, C(O)NR8R9, NR8R9, NR8SO2R9, OR8 , SO,NR3R4, or SR8;
W and Wz are independently selected NTDR3JTR544RβX, OR3, SR3, hydrogen, halogen, haloalkyl, COR3, CO2R3, CONR3R4, S(O)R3,
SO2R3, SO2NR3R4, SO3R3, P(O)(OR3)2, aldehyde, nitrile, nitro, alkyl,
T(CH2)mQR8, C(O)T(CH2)mQR8, or T(CH2)mCO2R8 where m is 1-6, T is
O, S, NR3, N(O)R3, NR3R4X, or CR3R4, and Q is O, S, NR9, N(O)R9 or NR9RI0X, or NR9C(O)T(CH2)mQR9;
R5 is hydrogen, or alkyl;
R6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR3, CO2R3,
CONR3R4, SO2NR3R4, SO2R3, SO3R3, P(O)(OR3)2, aldehyde, nitrile, nitro,
OR3, or NR3R4 W3 is NR3R4, N(O)R3R4, NR3R4R8X, OH, OR3, SH, SR3, halogen, COR3, CO2R3,
CONR3R4, S(O)R3, SO2R3, SO2NR3R4, SO3R3, (CH2)nP(O)(OR3)2,
NR3SO2R4, aldehyde, nitrile, nitro, alkyl, T(CH2)mQR8, C(O)T(CH2)mQR8,
NR8C(O)T(CH2)mQR", or T(CH2)mCO2R3 where m and n are independently 1-6, T is O, S, NR3, N(O)R3, NR3R4W, or CR3R4, and Q is O, S, NR9, N(O)R9 or NR9R10X;
R8, R9, R10 and R11 are hydrogen, alkyl, or aryl;
X is a halogen; or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof.
The compounds of the invention further comprise those of Formula II:
wherein, the dotted line represents a bond at the C5-C6, C6-C7, or C7-C8 position. R1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl,or heterocycloalkyl;
R2 is OH, alkyloxy, aryloxy, or NR3R4; A is N, or CW3; R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH2)nAr, cycloalkyl, heterocycloalkyl, or heteroaryl, or R3 and R4 together with the nitrogen to which they are attached optionally may form a ring having 3 to
7 carbon atoms and said ring optionally contains 1, 2 or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur including S(O) and S(O)2. Said ring also may be additionally substituted with up to 3 groups selected from alkyl, haloalkyl, NR8C(O)R9, C(O)OR8, C(O)R8, C(O)NR8R9, NR8R9, NR8SO2R9, OR8 ,
SO2NR3R4, or SR8; W1 and W2 are independently selected from NR3R4, N(O)R3R4, NR3R4R8X, OR3, SR3, hydrogen, halogen, haloalkyl, COR3, CO2R3, CONR3R4, S(O)R3, SO2R3, SO2NR3R4, SO3R3, P(O)(OR )2, aldehyde, nitrile, nitro, alkyl, T(CH2)mQR8, C(O)T(CH2)mQR8, or T(CH2)mCO2R8 where m is 1 -6, T is O, S, NR3, N(O)R3, NR3R4X, or CR3R4, and Q is O, S, NR9, N(O)R9 or
NR9R10X, or NR9C(O)T(CH2)mQR9; R5 is hydrogen, or alkyl;
R6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR3, CO2R3, CONR3R4, SO2NR3R4, SO2R3, SO3R3, P(O)(OR )2, aldehyde, nitrile, nitro,
OR3, or NR3R4 W3 is NR3R4, N(O)R3R4, NR3R4R8X, OH, OR3, SH, SR3, halo, COR3, CO2R3,
CONR3R4, S(O)R3, SO2R3, SO2NR3R4, SO3R3, (CH2)nP(O)(OR3)2,
NR3SO2R4, aldehyde, nitrile, nitro, alkyl, T(CH2)mQR8, C(O)T(CH2)mQR8, NR8C(O)T(CH2)mQR' ' , or T(CH2)mCO2R3 where n and m independently are 1-6; T is O, S, NR3, N(O)R3, NR3R4W, or CR3R4; and Q is O, S, NR9,
N(O)R9 or NR9Rl0X;
R8, R9, R10 and R11 are hydrogen, alkyl, or aryl;
X is a halogen; or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof.
Preferred examples of W3 include piperidine; piperidine substituted with up to 2 groups consisting of alkyl, haloalkyl, OR9, (CH2)nOR9, CO2R9, CONR9R10, NR9R10; 3-aminopyrrolidine, 3-acylaminopyrrolidine; 3- alkylaminopyrrolidine, 3-aminoalkylpyrrolidine; pyrrolidine substituted with up to 3 groups selected from alkyl, haloalkyl, NR8C(O)R9, C(O)NR8R9, NR8R9, OR8; piperazine; N-acylpiperazine; N-aminoacylpiperazine; piperazine substituted with up to five groups selected from alkyl, haloalkyl, OR8, (CH2)nOR8, CO2R8, ΝR8C(O)R9, C(O)NR8R9, NR8R9, SO2R, SO2NR8R9; piperazine substituted on nitrogen with a group selected from alkyl, haloalkyl, OR8, (CH2)„OR8, CO2R8,
CONR8R9, NR8R9, SO2R, SO2NR8R9; homopiperazine; N-acylhomopiperazine; N- alkylhomopiperazine; N-haloalkylhomopiperazine; tetrahydro- 1 ,4-pyrimidone.
Especially preferred groups include N-acetylpiperazine, 3,5-dimethylpiperazine, 3,3,4-trimethylpiperazinyl, N-methylpiperazine, homopiperazine, N- acetylhomopiperazine, N-tert-butylacetylpiperazine, N-pivaloylpiperazine, N- leucylpiperazine, N-isoleucylpiperazine; N-valylpiperazine, N-prolylpiperazine,
N-alanylpiperazine, and N-glycylpiperazine.
A preferred group of compounds of Formulas I and II have the above formulas wherein R1 is alkyl.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R is isopropyl.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R1 is cycloalkyl.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R1 is cyclopentyl.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R is hydroxy.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R is alkyloxy.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R is methoxy.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R2 is ΝR3R4. Another preferred group of compounds of Formulas I and II have the above formulas wherein A is CW3.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W3 is piperidine.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W3 is substituted piperidine.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W3 is pyrolidine.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W3 is substituted pyrolidine.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W is piperazine
Another preferred group of compounds of Formulas I and II have the above formulas wherein W3 is substututed piperazine.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W3 is hydrogen.
Another preferred group of compounds of Formulas I and II have the above formulas wherein W and W are hydrogen.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R5 is hydrogen.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R5 is alkyl.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R6 is hydrogen.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R6 is alkyl. Another preferred group of compounds of Formulas I and II have the above formulas wherein Wl, W^, and W^ are hydrogen.
Another preferred group of compounds of Formulas I and II have the above formulas wherein R^ and R > are hydrogen. A particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^, W^, and W^ are hydrogen, and R! is alkyl.
Another particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^, W^, and W^ are hydrogen, and R! is cycloalkyl. A further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^ is piperidine or substituted piperidine, and
R! is alkyl or cycloalkyl.
A further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^ is pyrrolidine or substituted pyrrolidine, and R! is alkyl or cycloalkyl.
A further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^ is piperazine or substituted piperazine, and R! is alkyl or cycloalkyl.
A further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^ is piperidine or substituted piperidine, R2 is alkyloxy, and R! is alkyl or cycloalkyl.
A further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^ is pyrrolidine or substituted pyrrolidine, R2 is alkyloxy, and R! is alkyl or cycloalkyl. A further particularly preferred group of compounds of Formulas I and II have the above formulas wherein W^ is piperazine or substituted piperazine, R2 is alkyloxy, and R! is alkyl or cycloalkyl.
The following compounds illustrate specific embodiments provided by the present invention, and the compounds listed below are among the preferred embodiments: (8-Isopropyl-7-methoxy-quinazolin-2-yl)-phenyl-amine; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-phenyl-amine; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperidin-l-yl-phenyl)-amine; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-l-yl-phenyl)- amine;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-piperidin-l-yl-phenyl)- amine;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-l-yl-phenyl)- amine; 8-Isopropyl-2-phenylamino-quinazolin-7-ol;
4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]-piperazine-l- carboxylic acid tert-butyl ester;
4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazine-1-carboxylic acid tert-butyl ester; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-piperazin- 1 -yl-phenyl)- amine;
8-Cyclopentyl-2-(4-piperazin-l-yl-phenylamino)-quinazolin-7-ol; 2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2-ylamino)- phenyl]-piperazin-l-yl}-ethanone; 8-Isopropyl-2-(4-piperazin- 1 -yl-phenylamino)-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperazin-l-yl-phenyl)-amine; 2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-quinazolin-2-ylamino)- phenyl]-piperazin-l-yl}-ethanone;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-ethanone;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl} -ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2-ylamino)- phenylj-piperazin- 1 -yl } -4-methyl-pentan- 1 -one; 2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -4-methyl-pentan- 1 -one; 2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
N-(4-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -4-oxo-butyl)-acetamide; N-(4-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-4-oxo-butyl)-acetamide;
N-(4-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-4-oxo-butyl)-acetamide;
N-(4-{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl}-4-oxo-butyl)-acetamide;
8-Isopropyl-2-(pyridin-4-ylamino)-quinazolin-7-ol; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-pyridin-4-yl-amine; (8-cyclopentyl-7-methoxy-quinazolin-2-yl)-pyridin-4-yl-amine; 8-cyclopentyl-2-(pyridin-4-ylamino)-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Isopropyl-2- [4-(5 -methyl-hexahydro-pyrrolo[3 ,4-c] pyrrol-2-y 1)- phenylamino]-quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-cyclopentyl-7-methoxy- quinazolin-2-yl)-amine; 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl-quinazolin-
7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-isopropyl-7-methoxy-quinazolin- 2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-isopropyl-quinazolin- 7-ol;
(4-Fluoro-3-trifluoromethyl-phenyl)-(8-isopropyl-7-methoxy-quinazolin- 2-yl)-amine;
2-(4-Fluoro-3-trifluoromethyl-phenylamino)-8-isopropyl-quinazolin-7-ol; (4-Fluoro-3-trifluoromethyl-phenyl)-(8-cyclopentyl-7-methoxy- quinazolin-2-yl)-amine;
2-(4-Fluoro-3-trifluoromethyl-phenylamino)-8-cyclopentyl-quinazolin- 7-ol; N-{ 1 -[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- pyrrolidin-3 -yl } -acetamide;
N-{ l-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- pyrrolidin-3-yl} -acetamide;
N- { 1 -[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- pyrrolidin-3-yl}-acetamide;
N-{ l-[4-(8-Isopropyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- pyrrolidin-3 -yl } -acetamide; l-{4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]-piperazin- l-yl}-ethanone; l-{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]-piperazin- l-yl}-ethanone;
{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-pyrrolidin-2-yl-methanone;
{4-[4-(8-Cyclopentyl-7-Hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl} -pyrrolidin-2-yl-methanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl}-ethanone; l-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl} -ethanone; {4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]-piperazin-l- yl } -pyrrolidin-2-yl-methanone;
{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]-piperazin-l- yl } -pyrrolidin-2-yl-methanone;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- l-yl}-propan-l -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -propan- 1 -one ; 2-Amino- 1 - {4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2-ylamino)- phenylj-piperazin- 1 -yl } -propan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]-piperazin- 1 -yl} -propan- 1 -one; l-{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]-piperazin- 1-yl} -propan- 1 -one;
8-Isopropyl-2-phenylamino-5,6-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-phenyl-amine; 8-Isopropyl-2-phenylamino-5,8-dihydro-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-phenyl-amine; 8-Cyclopentyl-2-phenylamino-5,6-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-phenyl-amine; 8-Cyclopentyl-2-phenylamino-5,8-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-phenyl-amine;
8-Isopropyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,6-dihydro-quinazolin- 7-ol;
(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-pyrrolidin-l-yl- phenyl)-amine; 8-Isopropyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,8-dihydro-quinazolin-
7-ol;
(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-pyrrolidin-l-yl- phenyl)-amine;
8-Cyclopentyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,6-dihydro-quinazolin- 7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-pyrrolidin-l- yl-phenyl)-amine; 8-Cyclopentyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,8-dihydro-quinazolin- 7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-pyrrolidin-l- yl-phenyl)-amine; 8-Isopropyl-2-(4-piperazin-l-yl-phenylamino)-5,6-dihydro-quinazolin-
7-ol;
(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-piperazin-l-yl- phenyl)-amine;
8-Isopropyl-2-(4-piperazin-l-yl-phenylamino)-5,8-dihydro-quinazolin- 7-ol;
(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-piperazin-l-yl- phenyl)-amine;
8-Cyclopentyl-2-(4-piperazin- 1 -yl-pheny lamino)-5 ,6-dihydro-quinazolin- 7-ol; (8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-piperazin-l-yl- phenyl)-amine;
8-Cyclopentyl-2-(4-piperazin-l-yl-phenylamino)-5,8-dihydro-quinazolin- 7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-piperazin-l-yl- phenyl)-amine;
2-(4-Fluoro-3-methyl-phenylamino)-8-isopropyl-5,6-dihydro-quinazolin- 7-ol;
(4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-5,6-dihydro- quinazolin-2-yl)-amine; 2-(4-Fluoro-3-methyl-phenylamino)-8-isopropyl-5,8-dihydro-quinazolin-
7-ol;
(4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-5,8-dihydro- quinazolin-2-yl)-amine;
8-Cyclopentyl-2-(4-fluoro-3-methyl-phenylamino)-5,6-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-fluoro-3- methyl-phenyl)-amine ; 8-Cyclopentyl-2-(4-fluoro-3-methyl-phenylamino)-5,8-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-fluoro-3- methyl-phenyl)-amine; 8-Isopropyl-2-(pyridin-4-ylamino)-5,6-dihydro-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-pyridin-4-yl-amine; 8-Isopropyl-2-(pyridin-4-ylamino)-5,8-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-pyridin-4-yl-amine; 8-Cyclopentyl-2-(pyridin-4-ylamino)-5,6-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-pyridin-4-yl- amine;
8-Cyclopentyl-2-(pyridin-4-ylamino)-5,8-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-pyridin-4-yl- amine; 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-isopropyl-5,6-dihydro- quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-isopropyl-7-methoxy-5,6- dihydro-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-isopropyl-5,8-dihydro- quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-isopropyl-7-methoxy-5,8- dihydro-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl-5,6-dihydro- quinazolin-7-ol; [4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-cyclopentyl-7-methoxy-5,6- dihydro-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl-5,8-dihydro- quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-cyclopentyl-7-methoxy-5,8- dihydro-quinazolin-2-yl)-amine;
8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-5,6-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-[4-(5-methyl- hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-5,8-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-[4-(5-methyl- hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-5,6-dihydro-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-[4-(5-methyl- hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-5,8-dihydro-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-[4-(5-methyl- hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine; l-{4-[4-(7-Hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -ethanone; l-{4-[4-(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -ethanone; l-{4-[4-(7-Hydroxy-8-isopropyl-5,8-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl}-ethanone; l-{4-[4-(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -ethanone; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -ethanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -y 1 } -ethanone ; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -ethanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-ylamino)- phenyl]-piperazin-l-yl}-ethanone; l-{4-[4-(7-Hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2-ylamino)- pheny 1] -piperazin- 1 -y 1 } -propan- 1 -one ; l-{4-[4-(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -y 1 } -propan- 1 -one; l-{4-[4-(7-Hydroxy-8-isopropyl-5,8-d_hydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -propan- 1 -one; l-{4-[4-(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2-ylamino)- pheny 1] -piperazin- 1 -y 1 } -propan- 1 -one ; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -propan- 1 -one; 2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl} -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl} -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -3-methyl-butan- 1 -one; 2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl} -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl} -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2- ylamino)-pheny 1] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one; 2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one; 2-A_mino-l-{4-[4-(8-isopropyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-pheny 1] -piperazin- 1 -y 1 } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2- ylamino)-pheny 1] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-pheny 1] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl} -4-methyl-pentan- 1 -one; 2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl } -ethanone;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l -yl} -ethanone;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl} -ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -ethanone; 2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -y 1 } -ethanone;
(4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)- amine;
2-(4-Fluoro-3-methyl-phenylamino)-8-isopropyl-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-fluoro-3-methyl-phenyl)- amine;
8-Cyclopentyl-2-(4-fluoro-3-methyl-phenylamino)-quinazolin-7-ol; (3-Chloro-4-fluoro-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)- amine;
2-(3-Chloro-4-fluoro-phenylamino)-8-isopropyl-quinazolin-7-ol; (3-Chloro-4-fluoro-phenyl)-(8-cyclopentyl-7-methoxy-quinazolin-2-yl)- amine;
2-(3-Chloro-4-fluoro-phenylamino)-8-cyclopentyl-quinazolin-7-ol; (3,4-Difluoro-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2-(3,4-Difluoro-phenylamino)-8-isopropyl-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3,4-difluoro-phenyl)-amine; 8-Cyclopentyl-2-(3,4-difluoro-phenylamino)-quinazolin-7-ol; (3-Fluoro-4-piperazin-l-yl-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2- yl)-amine;
2-(3-Fluoro-4-piperazin-l-yl-phenylamino)-8-isopropyl-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3-fluoro-4-piperazin-l-yl- phenyl)-amine;
8-Cyclopentyl-2-(3-fluoro-4-piperazin-l-yl-phenylamino)-quinazolin-7-ol; [4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenyl]-(8-isopropyl-7-methoxy- quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]-8-isopropyl- quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenyl]-(8-cyclopentyl-7-methoxy- quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]-8-cyclopentyl- quinazolin-7-ol;
{3-Fluoro-4-[4-(3-morpholin-4-yl-propyl)-piperidin-l-yl]-phenyl}-(8- isopropyl-7-methoxy-quinazolin-2-yl)-amine; 2-{3-Fluoro-4-[4-(3-morpholin-4-yl-propyl)-piperidin-l-yl]- phenylamino}-8-isopropyl-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)- { 3 -fluoro-4- [4-(3 -morpholin- 4-yl-propyl)-piperidin-l-yl]-phenyl}-amine; 8-Cyclopentyl-2-{3-fluoro-4-[4-(3-moφholin-4-yl-propyl)-piperidin-l-yl]- phenylamino } -quinazolin-7-ol ;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-morpholin-4-yl- propyl)-piperidin- 1 -yl] -phenyl} -amine; 8-Isopropyl-2-{4-[4-(3-moφholin-4-yl-propyl)-piperidin-l-yl]- phenylamino}-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-moφholin-4-yl- propyl)-piperidin-l-yl]-phenyl}-amine;
8-Cyclopentyl-2-{4-[4-(3-moφholin-4-yl-propyl)-piperidin-l-yl]- phenylamino}-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-piperazin-l-yl-propyl)- piperidin- 1 -yl]-phenyl} -amine;
8-Isopropyl-2-{4-[4-(3-piperazin-l-yl-propyl)-piperidin-l-yl]- phenylamino } -quinazolin-7-ol ; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-piperazin-l-yl- propyl)-piperidin- 1 -yl] -phenyl } -amine;
8-Cyclopentyl-2- {4- [4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl]- phenylamino} -quinazolin-7-ol;
{ 3 -Chloro-4- [4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl]-phenyl } -(8- isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2- { 3 -Chloro-4- [4-(3 -piperazin- 1 -y l-propyl)-piperidin- 1 -yl] -phenylamino} - 8-isopropyl-quinazolin-7-ol;
{3-Chloro-4-[4-(3-piperazin-l-yl-propyl)-piperidin-l-yl]-phenyl}-(8- cyclopentyl-7-methoxy-quinazolin-2-yl)-amine; 2- { 3 -Chloro-4- [4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl] -phenylamino } -
8-cyclopentyl-quinazolin-7-ol;
(3 -Fluoro-4- {4- [3 -( 1 H-tetrazol-5 -yl)-propy l]-piperidin- 1 -yl } -phenyl)-(8- isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2-(3-Fluoro-4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin-l-yl}- phenylamino)-8-isopropyl-quinazolin-7-ol;
(8-Cyclopenty l-7-methoxy-quinazolin-2-y l)-(3 -fluoro-4- { 4- [3 -( 1 H- tetrazol-5-yl)-propyl]-piperidin-l-yl}-phenyl)-amine; 8-Cyclopentyl-2-(3-fluoro-4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin-l- yl}-phenylamino)-quinazolin-7-ol;
(4- { 4- [3 -(3 - Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -y 1 } -3 -chloro- phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)-amine; 2-(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl] -piperidin- 1 -yl } -3 -chloro- phenylamino)-8-isopropyl-quinazolin-7-ol;
(4- {4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl] -piperidin- 1 -yl } -3 -chloro- phenyl)-(8-cyclopentyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- {4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propy l]-piperidin- 1 -yl } -3 -chloro- phenylamino)-8-cyclopentyl-quinazolin-7-ol;
(4-{4-[3-(3-Amino-pyrrolidin-l-yl)-propyl]-piperidin-l-yl}-phenyl)-(8- isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propy l]-piperidin- 1 -yl } - phenylamino)-8-isopropyl-quinazolin-7-ol; (4-{4-[3-(3-Amino-pyrrolidin-l-yl)-propyl]-piperidin-l-yl}-phenyl)-(8- cyclopentyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- { 4- [3 -(3- Amino-pyrrolidin- 1 -yl)-propyl] -piperidin- 1 -yl } - phenylamino)-8-cyclopentyl-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-{4-[4-(4-methoxy-phenyl)- piperazin- 1-yl] -phenyl} -amine;
8-Isopropyl-2-{4-[4-(4-methoxy-phenyl)-piperazin-l-yl]-phenylamino}- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-{4-[4-(4-methoxy-phenyl)- piperazin- 1-yl] -phenyl } -amine ; 8-Cyclopentyl-2-{4-[4-(4-methoxy-phenyl)-piperazin-l-yl]-phenylamino}- quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-[4-(3,3,4-trimethyl-piperazin-l- yl)-phenyl]-amine;
8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine; 8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-quinazolin-7-ol;
8-Isopropyl-2-[4-(3,3,4-trimethyl-piperazin-l-yl)-phenylamino]- quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(3,3,4-trimethyl-piperazin- l-yl)-phenyl] -amine;
8-Cyclopentyl-2-[4-(3,3,4-trimethyl-piperazin-l-yl)-phenylamino]- quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-perhydro- 1 ,4-diazepin- 1 - yl-phenyl)-amine;
8-Cyclopentyl-2-(4-perhydro-l ,4-diazepin- 1 -yl-phenylamino)-quinazolin- 7-ol; 2-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]-2,6- dimethyl -piperazin- 1-yl} -ethanol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(2-methylamino-ethoxy)- phenyl] -amine; l-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- perhydro- 1 ,4-diazepin- 1 -yl} -ethanone;
8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin- 1 -yl)-phenylamino]- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)- [4-(3 ,3 -dimethy 1-piperazin- 1 - yl)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- perhydro- 1 ,4-diazepin- 1 -y 1 } -ethanone;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-{4-[3-(lH-tetrazol-5-yl)- propyl] -piperidin- 1 -yl } -phenyl)-amine;
8-Cyclopentyl-2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin-l-yl}- phenylamino)-quinazolin-7-ol;
8-Cyclopentyl-N2-(4-piperazin-l-yl-phenyl)-quinazoline-2,7-diamine; 8-Cyclopentyl-N2-[4-(4-methyl-piperazin-l-yl)-phenyl]-quinazoline-2,7- diamine; l-{4-[4-(7-Amino-8-cyclopentyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -ethanone; 8-Cyclopentyl-N2-(4-perhydro-l,4-diazepin-l-yl-phenyl)-quinazoline-2,7- diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-quinazoline- 2,7-diamine;
8-Cyclopentyl-N^-methyl-N2-(4-piperazin-l-yl-phenyl)-quinazoline-2,7- diamine;
8-Cyclopentyl-N^-methyl-N2-[4-(4-methyl-piperazin-l-yl)-phenyl]- quinazoline-2,7-diamine; l-{4-[4-(8-Cyclopentyl-7-methylamino-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -y 1 } -ethanone; 8-Cyclopentyl-N7-methyl-N2-(4-perhydro- 1 ,4-diazepin- 1 -yl-phenyl)- quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-N^-methyl- quinazoline-2,7-diamine;
8-Cyclopentyl-N7,N'-dimethyl-N2-(4-piperazin-l-yl-phenyl)-quinazoline- 2,7-diamine;
8-Cyclopentyl-N^,N^-dimethyl-N2-[4-(4-methyl-piperazin-l-yl)-phenyl]- quinazoline-2,7-diamine; l-{4-[4-(8-Cyclopentyl-7-dimethylamino-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-ethanone; 8-Cyclopentyl-N^,N^-dimethyl-N2-(4-perhydro-l,4-diazepin-l-yl- phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-N'7,N7- dimethyl-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin-l-yl}- phenyl)-quinazoline-2,7-diamine; 8-Cyclopentyl-N7-methyl-N -(4-{4-[3-(lH-tetrazol-5-yl)-propyl]- piperidin-l-yl}-phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-{4-[4-(3-piperazin-l-yl-propyl)-piperidin-l-yl]- phenyl}-quinazoline-2,7-diamine; 8-Cyclopentyl-N^-methy 1-N2- { 4-[4-(3 -piperazin- 1 -yl-propy l)-piperidin- 1 - yl]-phenyl } -quinazoline-2,7-diamine;
8-Cyclopentyl-N^,N7-dimethyl-N2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin- 1 -yl]-phenyl } -quinazoline-2,7-diamine;
(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-(4-perhydro-l,4- diazepin-l-yl-phenyl)-amine;
8-Cyclopentyl-5-methyl-2-(4-perhydro-l,4-diazepin-l-yl-phenylamino)- quinazolin-7-ol;
2-{4-[4-(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-ylamino)- phenyl]-2,6-dimethyl-piperazin- 1 -yl } -ethanol; (8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-[4-(2-methylamino- ethoxy)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-ylamino)- phenyl]-perhydro-l ,4-diazepin- 1 -yl} -ethanone;
8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)-phenylamino]-5-methyl- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-[4-(3,3-dimethyl- piperazin-1 -yl)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5-methyl-quinazolin-2-ylamino)- phenyl]-perhydro-l ,4-diazepin-l -yl} -ethanone; (8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-(4-{4-[3-(lH- tetrazol-5 -yl)-propyl] -piperidin- 1 -yl } -phenyl)-amine;
8-Cyclopentyl-5-methyl-2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin-l- yl}-phenylamino)-quinazolin-7-ol; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5-methyl-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -y 1 } -ethanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -y 1 } -ethanone; 8-Cyclopentyl-5-methyl-2-(4-piperazin-l-yl-phenylamino)-quinazolin- 7-ol;
(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-(4-piperazin-l-yl- phenyl)-amine; (8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-{4-[4-(3-piperazin-
1 -yl-propyl)-piperidin- 1 -yl]-phenyl } -amine;
8-Cyclopentyl-5-methyl-2-{4-[4-(3-piperazin-l-yl-propyl)-piperidin-l-yl]- phenylamino}-quinazolin-7-ol;
8-Cyclopentyl-5-methyl-N2-(4-piperazin-l-yl-phenyl)-quinazoline-2,7- diamine;
8-Cyclopentyl-5-methyl-N2-[4-(4-methyl-piperazin-l-yl)-phenyl]- quinazoline-2,7-diamine; l-{4-[4-(7-Amino-8-cyclopentyl-5-methyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1-yl} -ethanone ; 8-Cyclopentyl-5-methyl-N2-(4-perhydro-l,4-diazepin-l-yl-phenyl)- quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-5-methyl- quinazoline-2,7-diamine;
8-Cyclopentyl-5,N^-dimethyl-N2-(4-piperazin-l-yl-phenyl)-quinazoline- 2,7-diamine;
8-Cyclopentyl-5,N^-dimethyl-N2-[4-(4-methyl-piperazin-l-yl)-phenyl]- quinazoline-2,7-diamine; l-{4-[4-(8-Cyclopentyl-5-methyl-7-methylamino-quinazolin-2-ylamino)- phenyl] -piperazin- 1-yl} -ethanone; 8-Cyclopentyl-5,N^-dimethyl-N2-(4-perhydro-l,4-diazepin-l-yl-phenyl)- quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-5,N7- dimethyl-quinazoline-2,7-diamine;
8-Cyclopentyl-5,N^,N^-trimethyl-N2-(4-piperazin-l-yl-phenyl)- quinazoline-2,7-diamine; 8-Cyclopentyl-5,N7,N7-trimethyl-N2-[4-(4-methyl-piperazin-l-yl)- phenyl]-quinazoline-2,7-diamine; l-{4-[4-(8-Cyclopentyl-7-dimethylamino-5-methyl-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl} -ethanone; 8-Cyclopentyl-5,N7,N7-trimethyl-N2-(4-perhydro- 1 ,4-diazepin- 1 -yl- phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-5,N7,N7- trimethyl-quinazoline-2,7-diamine;
8-Cyclopentyl-5-methyl-N -(4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin- l-yl}-phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-5 ,N7-dimethyl-N2-(4- {4- [3 -( 1 H-tetrazol-5 -y l)-propy 1] - piperidin-l-yl}-phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-5 -methyl-N2- { 4- [4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 - yl]-phenyl}-quinazoline-2,7-diamine; 8-Cyclopentyl-5,N7-dimethyl-N2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin-l-yl]-phenyl}-quinazoline-2,7-diamine; and
8-Cyclopentyl-5,N7,N7-trimethyl-N2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin- 1 -yl]-phenyl} -quinazoline-2,7-diamine.
Additional preferred embodiments of the present invention include those in Examples 1-10, 85, 54, and 57, infra.
Compounds of Formula I wherein R2 is alkyl, R^ and R > are hydrogen are especially useful as intermediates leading to compounds that display good inhibitory activity against cyclin-dependent kinases. Other especially useful intermediates leading to compounds that display good inhibitory activity against cyclin-dependent kinases are compounds of Formula III
wherein Rl, R2, R5. and R° are as defined above and X is oxygen or halogen.
Particularly useful intermediates are those wherein R2 is alkyloxy, R^ is hydrogen or alkyl, R6 is hydrogen, and R° is oxygen or chlorine or a pharmaceutically acceptable salt, ester, amide, or pro-drug thereof. The present invention also discloses processes for preparing compounds of
Formula I, II and III. These processes are described by the nonlimiting examples set forth below.
Unless otherwise expressly stated, the following definitions are adhered to throughout this disclosure. "Alkyl" means a straight or branched hydrocarbon radical having from
1 to 10 carbon atoms (unless stated otherwise) and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, iso- pentyl, n-hexyl, and the like. "Halo" includes fluoro, chloro, bromo, and iodo.
"Alkenyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one double bond and includes ethenyl, 3-buten-l-yl,
2-ethenylbutyl, 3-hexen-l-yl, and the like.
"Alkynyl" means straight and branched hydrocarbon radicals having from
2 to 6 carbon atoms and one triple bond and includes ethynyl, 3-butyn-l-yl, propynyl, 2-butyn-l-yl, 3-pentyn-l-yl, and the like. "Cycloalkyl" means a monocyclic or polycyclic hydrocarbyl group such as cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, noφinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl. Such groups can be substituted with groups such as hydroxy, keto, and the like. Also included are rings in which 1 to 3 heteroatoms replace carbons. Such groups are termed "heterocyclyl", which means a cycloalkyl group also bearing at least one heteroatom selected from O, S, orNR2, examples being substituted or unsubstituted oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, piperazinyl, acylpiperazinyl, pyrrolidinyl, and moφholine.
"Alkoxy" refers to the alkyl groups mentioned above bound through oxygen, examples of which include methoxy, ethoxy, isopropoxy, tert-butoxy, and the like. In addition, alkoxy refers to polyethers such as -O-(CH2)2" -CH3, and the like. "Alkanoyl" groups are alkyl linked through a carbonyl, ie, Ci -C5-C(O)-.
Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.
"Acyl" means an alkyl or aryl (Ar) group bonded through a carbonyl group, ie, R-C(O)-. For example, acyl includes a Cj-Cg alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by NR4R5 OΓ a carboxylic or heterocyclic group. Typical acyl groups include acetyl, benzoyl, and the like.
The alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted, preferably by 1 to 3 groups selected from NR4R5; phenyl, substituted phenyl, thio C j -Cg alkyl, C \ -Cg alkoxy, hydroxy, carboxy, C \ -C5 alkoxycarbonyl, halo, nitrile, cycloalkyl, and a 5- or 6-membered carbocyclic ring or heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, substituted nitrogen, oxygen, and sulfur. "Substituted nitrogen" means nitrogen bearing Cj-Cg alkyl or (CH2)nPh where n is 1, 2, or 3. Perhalo and polyhalo substitution is also embraced.
Examples of substituted alkyl groups include 2-aminoethyl, pentachloroethyl, trifluoromethyl, 2-diethylaminoethyl, 2-dimethylaminopropyl, ethoxycarbonylmethyl, 3-phenylbutyl, methanylsulfanylmethyl, methoxymethyl, 3-hydroxypentyl, 2-carboxybutyl, 4-chlorobutyl, 3-cyclopropylpropyl, pentafluoroethyl, 3-moφholinopropyl, piperazinylmethyl, and
2-(4-methylpiperazinyl)ethyl.
Examples of substituted alkynyl groups include 2-methoxyethynyl, 2-ethylsulfanyethynyl, 4-(l-piperazinyl)-3-(butynyl), 3-phenyl-5-hexynyl, 3-diethylamino-3-butynyl, 4-chloro-3-butynyl, 4-cyclobutyl-4-hexenyl, and the like.
Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, 3-hydroxypropoxy, 6-carboxhexyloxy, and the like.
Further, examples of substituted alkyl, alkenyl, and alkynyl groups include dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-l-yl,
5-ethylmethylamino-3-pentyn-l-yl, 4-moφholinobutyl, 4-tetrahydropyrinidylbutyl, 3-imidazolidin- 1 -ylpropyl, 4-tetrahydrothiazol-3-yl- butyl, phenylmethyl, 3-chlorophenylmethyl, and the like.
The terms "Ar" and "aryl" refer to unsubstituted and substituted aromatic groups. Heteroaryl groups have from 4 to 9 ring atoms, from 1 to 4 of which are independently selected from the group consisting of O, S, and N. Preferred heteroaryl groups have 1 or 2 heteroatoms in a 5- or 6-membered aromatic ring. Mono and bicyclic aromatic ring systems are included in the definition of aryl and heteroaryl. Typical aryl and heteroaryl groups include phenyl, 3-chlorophenyl, 2,6-dibromophenyl, pyridyl, 3-methylpyridyl, benzothienyl, 2,4,6-tribromophenyl, 4-ethylbenzothienyl, furanyl, 3,4-diethylfuranyl, naphthyl, 4,7-dichloronaphthyl, pyrrole, pyrazole, imidazole, thiazole, and the like.
Preferred Ar groups are phenyl and phenyl substituted by 1, 2, or 3 groups independently selected from the group consisting of alkyl, alkoxy, thio, thioalkyl, hydroxy, -COOR7, amino of the formula -NR4R5, and T(CH2)mQR4 or T(CH2)mCO2R4 wherein m is 1 to 6, T is O, S, NR4, N(O)R4, NR4R6Y, or
CR4R5, Q is O, S, NR5, N(O)R5, or NR5R6γ wherein R4 and R5 are as described above, and R7 is alkyl or substituted alkyl, for example, methyl, trichloroethyl, diphenylmethyl, and the like. The alkyl and alkoxy groups can be substituted as defined above. For example, typical groups are carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, hydroxyalkoxy, and alkoxyalkyl.
The symbol "-" means a bond.
The term "patient" means all animals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, and pigs.
The compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
The compounds of Formulas I, II, and III are capable of further forming both pharmaceutically acceptable formulations comprising salts, esters, amides, and prodrugs. As used herein, the term "pharmaceutically acceptable salts, esters, amides, and prodrugs" refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed and including, but not limited to, acid addition and/or base salts, solvents and N-oxides of a compound of Formulas I, II, and III. This invention also provides pharmaceutical formulations comprising a compound of Formulas I, II, or III together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. All of these forms are within the present invention. Pharmaceutically acceptable acid addition salts of the compounds of
Formulas I, II and III include salts derived form inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are the salts of amino acids such as arginate, gluconate, galacturonate, and the like; see, for example, Berge, et al., "Pharmaceutical Salts," J. of Pharmaceutical Science, 1977;66:1-19.
The acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for puφoses of the present invention. Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine; see, for example, Berge, et al., supra.
The base addition salts of acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for puφoses of the present invention.
Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include Cj-Cgalkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include Cf-C cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C]-C4alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary
Ci -Cgalkyl amines and secondary Ci -Cgdialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, Ci -C alkyl primary amines, and Ci -C2dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods. The term "pro-drug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987, both of which are incoφorated herein by reference.
A therapeutically effective amount is an amount of a compound of Formulas I, II, or III, that when administered to a patient, ameliorates a symptom of the disease.
The term "cardiovascular disorders and diseases" includes, but is not limited to atherosclerosis, psoriasis, and restenosis. Those skilled in the art are easily able to identify patients having atherosclerosis, psoriasis, restenosis, or at risk of having atherosclerosis or restenosis. For example, patients who are at risk of having restenosis include, but are not limited to, patients having undergone balloon angioplasty or other surgical vascular procedures.
The term "cancer" includes, but is not limited to, the following cancers: breast; ovary; cervix; prostate; testis; esophagus; glioblastoma; neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoid carcinoma, large cell carcinoma, adenocarcinoma; bone; colon, adenocarcinoma, adenoma; pancreas, adenocarcinoma; thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladder carcinoma; liver carcinoma and biliary passages; kidney carcinoma; myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine; colon-rectum, large intestine, rectum; brain and central nervous system; and leukemia.
The term autoimmune disease includes, but is not limited to inflammation, such as rheumatoid arthritis, and organ graft rejections.
The term kidney disease includes, but is not limited to kidney disease, such as polycystic kidney disease.
Compounds within the scope of the present invention effectively inhibit vascular smooth muscle cell proliferation and migration. The method entails inhibiting vascular smooth muscle proliferation, and/or migration by administering an effective amount of a compound of Formulas I, II, or III to a subject in need of treatment.
The compounds of the present invention are useful for treating cancer (for example, leukemia and cancer of the lung, breast, prostate, and skin such as melanoma), cardiovascular disorders and diseases, infections, autoimmune diseases, gout, kidney diseases, and neurodegenerative diseases and disorders. To utilize a compound of the present invention to treat these indications, a patient having the indication is administered a therapeutically effective amount of a pharmaceutically acceptable composition comprising an invention compound. The term "neurological disease and disorders" includes, but is not limited to, Alzheimer's disease. Compounds within the scope of the present invention effectively inhibit the degradation of neurons. The method entails inhibiting neural degeneration by administering an effective amount of a compound of Formulas I, II, or III to a subject in need of treatment. The compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms, including transdermal and rectal administration. It will be recognized to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formulas I, II, or III or a corresponding pharmaceutically acceptable salt or solvate of a compound of Formulas I, II, or III.
A further embodiment of this invention is a pharmaceutical formulation comprising a compound of Formulas I, II, or III together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. For preparing pharmaceutical compositions with the compounds of the present invention, pharmacuetically acceptable carriers can be either a solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid such as talc or starch which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The formulations of this invention preferably contain from about 5% to about 70% or more of the active compound. Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. A preferred form for oral use are capsules, which include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogenously therein, as by stirring. The molten homogenous mixture is then poured into convenient size molds, allowed to cool, and thereby to solidify. Liquid form preparations include solutions, suspensions, and emulsions such as water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution, isotonic saline, 5% aqueous glucose, and the like. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water and mixing with a viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. Waxes, polymers, microparticles^ and the like can be utilized to prepare sustained-release dosage forms. Also, osmotic pumps can be employed to deliver the active compound uniformally over a prolonged period. The pharmaceutical preparations of the invention are preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampules.
Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The therapeutically effective dose of a compound of Formulas I, II, or III will generally be from about 1 mg to about 100 mg/kg of body weight per day. Typical adult doses will be about 50 mg to about 800 mg per day. The quantity of active component in a unit dose preparation may be varied or adjusted from about 0.1 mg to about 500 mg, preferably about 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents. A subject in need of treatment with a compound of Formulas I, II, or III is administered a dosage of about 1 to about 500 mg per day, either singly or in multiple doses over a 24-hour period.
The compounds of the present invention are capable of binding to and inhibiting the activity of proteins having the ability to phosphorylate other proteins, such as cdks. Cdks form complexes with cyclins, and these complexes phosphorylate key proteins allowing cells to proceed through the cell cycle (Meijer L., Progress in Cell Cycle Research, 1995;1 :351-363). The compounds of this invention inhibit this phosphorylation and therefore can be used as anti- proliferative agents for the treatment of cancer and/or restenosis and other proliferative diseases, and as anti-neural degenerative agents for the treatment of neural degenerative disorders such as Alzheimer's disease.
Because of their inhibitory activity against cdks and other kinases, the compounds of the present invention are also useful research tools for studying the mechanism of action of those kinases, both in vitro and in vivo. While the forms of the invention herein constitute presently preferred embodiments, many others are possible. It is not intended herein to mention all of the possible equivalent forms or ramifications of the invention. It is understood that the terms used herein are merely descriptive rather than limiting, and those skilled in the art will realize that various changes may be made without departing from the spirit or scope of the invention.
Compounds of Formulas I, II, and III may be prepared according to the syntheses outlined in Scheme 1, infra. Although this scheme often indicates exact structures, those with ordinary skill in the art will appreciate that the methods apply widely to analogous compounds of Formulas I, II, and III, given appropriate consideration to protection and deprotection or reactive functional groups by methods standard to the art of organic chemistry. For example, hydroxy groups, in order to prevent unwanted side reactions, generally need to be converted to ethers or esters during chemical reactions at other sites in the molecule. The hydroxy protecting group is readily removed to provide the free hydroxy group. Amino groups and carboxylic acid groups are similarly derivatized to protect them against unwanted side reactions. Typical protecting groups and methods for attaching and cleaving them are described fully by Greene and Wuts in Protective Groups in Organic Synthesis, John Wiley and Sons, New York, (2nd Ed., 1991), and McOmie, Protective Groups in Organic Chemistry, Plenum Press, New York, 1973.
Scheme 1 describes a typical method for the preparation of the quinazoline compounds of the invention.
Scheme 1
(1) (2) (3) aqHCI NaOCH3/THF NaH/EtOCHO Benzene
(4) (5) Guanidine carbonate 10%Pd-C
DMF y nitrobenzene
(6) (7)
(8) (9) (10)
R -NHπ NaSEt
(11) (12)
Schemes 2 and 3
Scheme 2
(16)
Scheme 3
(1) v
NH
BocN^NHBoc (ref Bernatowivz et al
NH. <^N^NH2 Tetrahedron Lett 1993, 34, 3389)
(2) TFA
(17)
EXAMPLES
The following examples are for illustrative puφoses only and are not intended, nor should they be construed as limiting the invention in any manner. Those skilled in the art will appreciate that variations and modifications can be made without violating the spirit or scope of the invention.
EXAMPLE 1 1 ,5-Dimethoxy-cyclohexa-l ,4-diene
A solution containing 1,3-dimethoxybenzene (10 g), dry THF (15 mL) and *BuOH (15 mL) was added to distilled ammonia (ca 250 mL). To the reaction mixture was added lithium wire (1.5 g) in small portions, and the deep blue colored solution was stirred for 3 hours. The reaction mixture was decolorized by dropwise addition of methanol. Ammonia was evaporated at room temperature. To the residue, ammonium chloride solution was added, then the product was extracted with hexane (3 x 120 mL). The combined extracts were washed with water and dried over anhydrous sodium sulfate. Removal of the solvent under reduced pressure gave the title compound as a clear liquid (9.5 g). ^H NMR (CDC13): δ 2.7-2.9 (m, 4H, 2 x CH2), 3.58 (s, 6H, 2 x OCH3), 4.66 (t, 2H, olefinic).
EXAMPLE 2
6-Isopropyl- 1 ,5-dimethoxy-cyclohexa- 1 ,4-diene
To a solution of l,5-dimethoxy-cyclohexa-l,4-diene (7 g, 50 mmol) in dry THF (140 mL) was added dropwise nBuLi solution (2.5 M, 30 mL) in hexane at -20°C. The orange colored reaction mixture was stirred for 0.5 hour at -20°C, then isopropyl iodide (17 g, 100 mmol) was added dropwise. The reaction mixture was stirred for 1 hour, while the temperature was raised to 0°C. Excess nBuLi was destroyed cautiously with methanol. Cold water (140 mL) was added to the reaction mixture, then the product was extracted with ethyl acetate (3 x 70 mL). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, and concentrated to give the title compound as a light yellow liquid (8.5 g, 93.4%). *H NMR CDC13): δ 0.90 (d, 6H, 2 x CH3), 2.1 (m, IH, CH), 2.76 (m, 3H, CH2 and CH), 3.53 (s, 6H, 2 x OCH3), 4.73 (t, 2H, olefinic).
EXAMPLE 3 2-Isopropyl-3 -methoxy-cyclohex-3 -enone
To a solution of 6-isopropyl-l,5-dimethoxy-cyclohexa-l,4-diene (7 g) in methanol (50 mL) was added 2.5% hydrochloric acid (10 mL) drop wise at 0°C. The reaction mixture was stirred for 45 minutes, then diluted with ice-cold water (30 mL). The product was extracted with ether (3 x 70 mL). The combined organic extracts were washed with brine and dried over anhydrous sodium sulfate.
Removal of the solvent in vacuo yielded the title compound as a light yellow oil (6 g, 93%).
EXAMPLE 4 2-Isopropyl-3-methoxy-cyclohex-2-enone To a solution of 2-isopropyl-3-methoxy-cyclohex-3-enone (6 g) in dry THF
(120 mL), sodium methoxide (1.5 g) was added in portions at room temperature. After stirring at room temperature for 1.5 hours, the reaction mixture was cooled in an ice bath and neutralized with 10% sodium hydrogen phosphate solution. The organic layer was separated, then the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with brine, then dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the resulting product was purified on a column of silica gel
(Hex:EtOAc) to give the title compound as a yellow liquid (5.4 g, 90%). ^H NMR (CDCI3): δ 1.09 (d, 6H, 2 x CH3), 1.95 (m, 2H, CH2), 2.31 (t, 2H, CH2), 2.54 (t, 2H, CH2), 3.2 (m, IH, CH), 3.78 (s, 3H, OCH3).
EXAMPLE 5 6-Hydroxymethylene-2-isopropyl-3-methoxy-cyclohex-2-enone To a suspension of sodium hydride (3.6 g, 60% suspension, 90 mmol) in benzene (100 mL), a mixture of ethyl formate (12.5 g) and 2-isopropyl-3 -methoxy- cyclohex-2-enone (5 g, 29.7 mmol) in benzene was added dropwise at 5°C. The reaction mixture was stirred at ice temperature for 1 hour, and at room temperature for 18 hours. The reaction mixture was cooled in an ice bath, and 10%) sodium hydrogen phosphate solution (200 mL) was added dropwise. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine and dried over anhydrous sodium sulfate. The solvent was removed in vacuo, and the resulting product was purified on a column of silica gel (Hex:EtOAc) to give the title compound as a thick viscous liquid (3.5 g, 60%). lH NMR (CDCI3): δ 1.15 (d, 6H, 2 x CH3), 2.35-2.6 (m, 4H, 2 x CH2), 3.15 (m, IH, CH), 3.8 (s, 3H,
OCH3), 7.17 (d, IH, =CHOH).
EXAMPLE 6 8-Isopropyl-7-methoxy-quinazolin-2-ylamine A mixture of 6-hydroxymethylene-2-isopropyl-3-methoxy-cyclohex-2-enone (3.5 g) and guanidine carbonate (7 g) in DMF (40 mL) was heated at 150°C for
4 hours. The solvent was removed under reduced pressure, then ice-cold water was added to the residue. The product was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water, then brine, and dried over anhydrous sodium sulfate. Solvent was removed under reduced pressure to give a crude mixture of dihydroquinazolines (4 g). The dihydroquinazolines were aromatized to the title compound by heating in nitrobenzene (70 mL) at 150°C in the presence of 10% Pd-C (400 mg) for 3 days. The catalyst was removed by filtration, then the filtrate was concentrated, and the resulting product was purified on a column of silica gel (Hex:EtOAc) to give the title compound as an off-white solid (2.1 g, 54.2%), mp 1 12-113°C; lH NMR
(CDCI3): δ 1.38 (d, 6H, 2 x CH3), 3.95 (s, 3H, OCH3), 4.24 (m, IH, CH), 5.0 (br s, 2H, NH2), 7.02 (d, IH, Ar-H, J = 9 Hz), 7.55 (d, IH, Ar-H, J = 9 Hz), 8.87 (s, IH, Ar-H); MS m/z 218.05, C12H15N3O (M++1). EXAMPLE 7 8-Isopropyl-7-methoxy- 1 H-quinazolin-2-one
To a solution of 2-amino-7-methoxy-8-(2-propyl)quinazoline (1.3 g) in tetrafluoroboric acid (50 mL), sodium nitrite solution (2.6 g in 10 mL of water) was added dropwise at 0°C. The reaction mixture was stirred at 0°C for 1 hour and at room temperature for 18 hours. The reaction mixture was cooled in an ice bath and neutralized with 30% ammonia solution. The product was extracted with ethyl acetate (3 x 50 mL), combined organic extract was washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the title compound as an off-white solid (1.2 g, 92.3%), mp
188-190°C (decom); lH NMR (CDCl3): δ 1.32 (d, 6H, 2 x CH3), 3.44 (m, IH, CH), 3.97 (s, 3H, OCH3), 6.88 (d, IH, Ar-H, J=8.8 Hz), 7.59 (d, IH, Ar-H, 8.8Hz), 9.0 (s, IH, Ar-H), 9.1 (brs, IH, NH).
EXAMPLE 8
2-Chloro-8-isopropyl-7-methoxy-quinazoline
7-Methoxy-8-(2-propyl)quinazol-2(lH)-one (1.2 g) was dissolved in 25 mL of phosphorus oxychloride, and the resulting reaction mixture was heated at 110°C for 2 hours. Excess POCI3 was removed under reduced pressure. To the residue ice-cold water was added, and the product was extracted with ethyl acetate
(3 x 50 mL). The combined organic extract was washed with brine, dried over anhydrous sodium sulfate, and concentrated to give the title compound. This was purified on a column of silica gel (Hexane:Ethyl acetate), off-white solid,
(780 mg, 60%), mp 135-137°C; !H NMR (CDCI3): δ 1.41 (d, 6H, 2 x CH3), 4.02 (s, 3H, OCH3), 4.33 (m, IH, CH), 7.38 (d, IH, Ar-H, J = 9 Hz), 7.8 (d, IH,
Ar-H, J = 9 Hz), 9.1 (s, IH, Ar-H).
EXAMPLE 9 (8-Isopropyl-7-methoxy-quinazolin-2-yl)-phenyl-amine
A mixture of 2-chloro-7-methoxy-8-(2-propyl)quinazoline (100 mg, 0.42 mmol) and aniline (120 mg, 1.29 mmol) in acetonitrile (3 mL) was heated at 80°C for 18 hours in a sealed tube. The solvent was removed under reduced pressure, to the residue 5% sodium carbonate solution was added. The product was extracted with ethyl acetate (3 x 25 mL). The combined organic extract was washed with brine, dried (Na2SO4), and concentrated. The product was purified on a column of silica gel to give the title compound as an off-white solid. (95 mg, 76.3%), mp
172-173°C; lU NHR (CDCI3): δ 1.46 (d, 6H, 2 x CH3), 3.97 (s, 3H, OCH3), 4.33 (m, IH, CH), 7.0-7.1 (m, 2H, Ar-H), 7.38 (t, 2H, Ar-H, 7.58 (d, IH, Ar-H), 7.85 m, 2H, Ar-H), 8.93 (s, IH, Ar-H); MS m/z C^H^^O 294.21 (M++1); Analysis: Calcd.: C, 73.7; H, 6.53; N, 14.32. Found: C, 73.8; H, 6.83; N, 14.59.
EXAMPLE 10
6-Cyclopentyl- 1.5-dimethoxy-cyclohexa- 1 ,4-diene
To a solution of 2,5 -dihydro- 1,3-dimethoxybenzene (9.88 g, 70 mmol) in dry THF (150 mL) was added dropwise nBuLi solution (2.5 M, 42.4 mL) in hexane at -20°C. The orange colored reaction mixture was stirred for 0.5 hour at -20°C, then cyclopentyl bromide (20.9 g, 140 mmol) was added dropwise. The reaction mixture was stirred for 1 hour at -20°C to 0°C. Excess nBuLi was destroyed cautiously with methanol. To the reaction mixture, 140 mL of cold water was added. The product was extracted with ethyl acetate (3 x 80 mL). The combined organic extract was washed with brine, dried over anhydrous sodium sulfate, and concentrated to give the title compound as light yellow liquid (14.12 g, 96.8%). iH NMR: δ 1.0-2.4 (Complex, 9H), 2.7-2.94 (m, 3H), 3.52 (s, 6H, 2 x OCH3), 4.70 (t, 2H).
EXAMPLE 11 2-Cyclopentyl-3 -methoxy-cyclohex-3 -enone To a solution of 2-cyclopentyl-2,5-dihydro-l,3-dimethoxybenzene ( 5 g, 27 mmol) in methanol (50 mL) was added 2.5% hydrochloric acid (10 mL) dropwise at 0°C. The reaction mixture was stirred for 45 minutes and diluted with 30 mL of ice- cold water. The, product was extracted with ether (3 x 100 mL). The combined organic extract was washed with brine and dried (Na2SO4). Removal of the solvent in vacuo yielded the title compound as light yellow oil (4.3 g, 94.7%).
EXAMPLE 12 2-Cyclopentyl-3-methoxy-cyclohex-2-enone To a solution of 2-cyclopentyl-3-methoxycyclohex-3-en-l-one ( 4.3 g) in dry THF
(120 mL), sodium methoxide (1.1 g) was added in portions at room temperature. After stirring the reaction mixture at room temperature for 1.5 hours, cooled in an ice bath, and neutralized with sodium hydrogen phosphate solution. The organic layer was separated, aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the resulting product was purified on a column of silica gel (Hex:EtOAc) to give the title compound as yellow liquid (2.82 g, 65.5%). ]H NMR (CDC13): δ
1.25-1.8 (m, 8H, 4 x CH2), 1.96 (m, 2H, CH2), 2.36 (t, 2H,CH2), 2.56 (t, 2H, CH ), 3.22 (m, IH, CH), 3.79 (s, 3H, OCH3).
EXAMPLE 13 2-Cvclopentyl-6-hydroxymethylene-3-methoxy-cyclohex-2-enone To a suspension of sodium hydride (2.04 g, 60% suspension, 51 mmol) in benzene (100 mL), a mixture of ethyl formate (6.7 mL) and 2-cyclopentyl- 3-methoxycyclohex-3-en-l-one (2.82 g, 17 mmol) in benzene was added dropwise at 5°C. The reaction mixture was stirred at ice temperature for 1 hour and 18 hours at room temperature. The reaction mixture was cooled in ice bath, and 200 mL of 10% sodium hydrogen phosphate solution was added dropwise. The organic layer was separated, and aqueous layer was extracted with ethyl acetate (2 x 50 mL). Combined organic extract was washed with brine and dried over anhydrous sodium sulfate. Solvent was removed in vacuo and the resulting product was purified on a column of silica gel (Hex:EtOAc) to give the title compound as a viscous liquid (2 g, 60%). EXAMPLE 14 8-Cyclopentyl-7-methoxy-quinazolin-2-ylamine
A mixture of 6-formyl-2-cyclopentyl-3 -methoxy cyclohex-2-en-l -one (2.0 g, 10.2 mmol) and guanidine carbonate (4.6 g) in DMF (30 mL) was heated at 150°C for 4 hours. The solvent was removed under reduced pressure and to the residue ice-cold water was added. The product was extracted with ethyl acetate (3 x 50 mL). The combined organic extract was washed with water and brine and dried over anhydrous sodium sulfate. Solvent was removed under reduced pressure to give 2.0 g of crude dihydroquinazoline. The dihydroquinazoline was aromatized to the title compound by heating in nitrobenzene at 150°C in the ' presence of 10%> Pd-C. To a solution of dihydroquinazoline (2.0 g, 8.2 mmol) in nitrobenzene (20 mL), 200 mg of 10%) Pd-C was added, and the reaction mixture was heated at 150°C for 3 days. The Pd-C was removed by filtration. The filtrate was concentrated, and the resulting product was purified on a column of silica gel (Hex:EtOAc) to give the title compound as an off-white solid (1 g, 50% yield), mp
181-183°C; !H NMR (CDC1 ): δ 1.6-2.2 (complex, 8H, 4 x CH2), 3.9 (s, 3H, OCH3), 4.27 (t, IH, CH), 5.02 (brs, 2H, NH2), 7.02 (d, IH, Ar-H, J = 9 Hz), 7.54 (d, IH, Ar-H, J = 9 Hz), 8.87 (s, IH, Ar-H); MS: m/z 244.07, C14Hι7N3O
(M++1).
EXAMPLE 15
8-Cyclopentyl-7-methoxy-lH-quinazolin-2-one
To a solution of 2-amino-8-cylopentyl-7-methoxyquinazoline (1.38 g,) in tetrafluoroboric acid (30 mL), sodium nitrite solution (1.16 g in 10 mL of water) was added dropwise at 0°C. The reaction mixture was stirred at 0°C for 1 hour and at room temperature for 18 hours. The reaction mixture was cooled in a ice bath and neutralized with 30% ammonia solution. The product was extracted with ethyl acetate (3 x 50 mL), combined organic extract was washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the title compound as a orange solid (1.0 g, 73%), mp 201-204°C; ]H NMR (CDCI3): δ 1.7-2.0 (complex, 8H, 4 x CH ), 3.43 (m, IH, CH), 3.96 (s, 3H, OCH3), 6.89 (d, IH, Ar-H, J = 8.8 Hz), 7.59 (d, IH, Ar-H, J = 8.8 Hz),
8.92 (brs, IH, NH), 9.03 (s, IH, Ar-H).
EXAMPLE 16 2-Chloro-8-cyclopentyl-7-methoxy-quinazoline 7-Methoxy-8-(2-propyl)quinazol-2(lH)-one (0.95 g) was dissolved in 40 mL of phosphorus oxychloride, and the resulting reaction mixture was heated at 110°C for 4 hours. Excess POCI3 was removed under reduced pressure. To the residue ice-cold water was added, and the product was extracted with ethyl acetate (3 x 50 mL). The combined organic extract was washed with brine, dried over anhydrous sodium sulfate, and concentrated to give the chloro compound. This was purified on a column of silica gel (Hexane :Ethyl acetate), beige solid,
(710 mg, 69% yield), mp 250°C (decomp); *H NMR (CDCI3): δ 1.7-2.0 (complex, 8H, 4 x CH2), 4.17 (s, 3H, OCH3), 4.27 (m, IH, CH), 7.65 (d, IH, Ar-H, J = 9 Hz ), 8.30 (d, IH, Ar-H), 9.71 (s, IH, Ar-H).
EXAMPLE 17
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-phenyl-amine A mixture of 2-chloro-7-methoxy-8-(2-propyl)quinazoline (200 mg, 0.76 mmol) and aniline (212 mg, 2.28 mmol) in acetonitrile (3 mL) was heated at 90°C for 60 hours in a sealed tube. The solvent was removed under reduced pressure, to the residue 5% sodium carbonate solution was added. The product was extracted with ethyl acetate (3 x 40 mL). The combined organic extract was washed with brine, dried (Na2SO4), and concentrated. The product was purified on a column of silica gel to give the title compound as a yellow solid (90 mg, 37%), mp 187-188°C;
]H NMR (CDCI3) δ: 1.72-2.30 (complex, 8H, 4 x CH2), 3.96 (s, 3H, OCH3), 4.33 (m, IH, CH), 7.23-7.41 (m, 2H, Ar-H), 7.58 (d, IH, Ar-H), 7.83 (d, 2H,
Ar-H), 8.93 (s, IH, Ar-H); MS: m/z 319.81, C20H21N3O; Analysis: Calcd.:
C, 75.21 ; H, 6.63; N, 13.16. Found: C, 75.03; H, 6.73; N, 13.05. EXAMPLE 18 General procedure for coupling anilines
A mixture of 2-chloroquinazoline (0.03 mmol) and the appropriate aniline (0.09 mmol) in acetonitrile (5 mL) was heated in a sealed tube for 24 to 72 hours at 110°C. Solvent was removed under reduced pressure, and the residue was suspended in ethyl acetate and treated with 5% Na2CO3 solution. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic extracts were washed with brine and dried over Na2SO4. The product was purified by chromatography on silica gel.
EXAMPLE 19
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-phenyl-amine
mp.172- 173 °C; 1H NHR (CDC13) δ 1.46 (d, 6H, 2xCH3), 3.97 (s, 3H, OCH3), 4.33 (m, IH, CH), 7.0-7.1 (m, 2H, Ar-H), 7.38 (t, 2H, Ar-H, 7.58 (d, IH, Ar-H), 7.85 m, 2H, Ar-H), 8.93 (s, IH, Ar-H); MS: m/z C18Hι9N3O 294.21 (M++l); Analysis: Calcd.: C 73.7, H 6.53, N 14.32; Found: C 73.8, H 6.83, N 14.59
EXAMPLE 20 l-{4-r4-(8-Cyclopentyl-7-methoxy-quinazolin-2-yIamino)-phenyl1-piperazin-l- yl} -ethanone
Yellow solid, yield 83%, mp 247-249 °C;Η NMR (CDC13) δ: 1.6- 2.3 (complex,
8H, 4XCH2), 2.18 (s, 3H, COCH3), 3.13 (m, 4H), 3.63 (m, 2H), 3.78 (m, 2H),
3.96 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.96 (d, 2H, Ar-H, J=9 Hz), 7.05 (d, IH,
Ar-H, J=8.8 Hz), 7.11 (s, IH, NH), 7.56 (d, IH, Ar-H, J=8.8 Hz), 7.72 (d, 2H, Ar- H, J=9Hz), 8.90 (s, IH, Ar-H); MS (ES): m z 446.29, C26H3ιN5O2, (MH+).
Analysis: Calcd.: C, 70.09; H, 7.01, N, 15.72. Found: C, 69.38; H, 7.43; N, 15.06
EXAMPLE 21
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperidin-l-yl-phenyl)-amine
Yellow solid, Yield 54.5%, mp 166-167°C; !H NMR (CDCI3): δ 1.44 (d, 6H,
2 x CH3), 1.6 (m, 2H, CH2), 1.74 (m, 4H, 2 x CH2), 3.13 (t, 4H, 2 x CH2),
3.96 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.9-7.1 (2d and s merged, 3 Ar-H, NH), 7.54 (d, IH, Ar-H), 7.7 (d, 2H, Ar-H). 8.88 (s, IH, Ar-H); MS (ES): m z 376.97,
C23H28N4O (M+); Analysis: Calcd.: C, 73.37; H, 7.5; N, 14.88. Found: C, 73.18;
H, 7.69; N, 14.89.
EXAMPLE 22
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-l -yl-phenyl)-amine
Orange solid, 64.7%, mp 188-190°C; !H NM (CDCI3): δ 1.43 (d, 6H, 2 x CH3),
2.01 (m, 4H, 2 x CH2), 3.30 (t, 4H, 2 x CH ), 3.95 (s, 3H, OCH3), 4.29 (m, IH
CH), 6.61 (d, 2H, Ar-H, J = 8.9 Hz), 6.9-7.1 (d and s merged, 2H, 1 Ar-H, NH), 7.52 (d, IH, Ar-H, J = 8.9 Hz), 7.63 (d, 2H, Ar-H, J = 8.9 Hz), 8.85 (s, IH, Ar-H);
MS (ES): m/z 363.02, C22H26N4O (M++1); Analysis: Calcd., C, 72.90; H, 7.23;
N, 15.46. Found: C, 73.35; H, 7.67; N, 14.74. EXAMPLE 23 (8-Cvclopentyl-7-methoxy-quinazolin-2-yl)-(4-piperidin-l-yl-phenyl)-amine
Yellow solid, 28% yield, mp 212-214°C; !H NMR (CDC13): δ 1.55-2.28
(complex, 14H, 7 x CH2), 3.08-3.14 (m, 4H, 2 x CH2), 3.95 (s, 3H, OCH3), 4.29 (m, IH, CH), 6.94-7.08 (complex, 4H, 3 Ar-H, NH), 7.52-7.57 (m, IH, Ar-H),
7.65-7.72 (m, 2H, Ar-H), 8.88 (s, IH, Ar-H); MS (ES): m/z 403.17, C25H30N4O
(M++1); Analysis: Calcd.: C, 74.60; H, 7.51; N, 13.92. Found: C, 74.83, H, 7.57, N, 13.82.
EXAMPLE 24 (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-l-yl-phenyl)-amine
Yellow solid, yield 42.7%, mp 240-242°C; *H NMR (CDCI3): δ 1.68-2.29
(complex, 12H, 6 x CH2), 3.30 (m, 4H, 2 x CH2), 3.94 (s, 3H, OCH3), 4.28 (m,
IH, CH), 6.59 (d, 2H, Ar-H, J = 8.9 Hz), 6.95 (s, IH, NH), 7.0 (d, IH, Ar-H, J = 8.9 Hz, ), 7.52 (d, IH, Ar-H, J = 8.9 Hz), 7.60 (d, 2H, Ar-H, J = 8.9 Hz), 8.86 (s, IH, Ar-H); MS (ES): m/z 388.98, C24H28N4O (M+); Analysis: Calcd.:
C, 74.20; H, 7.26; N, 14.42. Found: C, 73.94, H, 7.34, N, 14.36.
EXAMPLE 25 4-r4-(8-Isopropyl-7-methoxy-quinazolin-2-ylaminoVphenyl.-piperazine-
1 -carboxylic acid tert-butyl ester Yellow solid, yield 64.4%, mp 173-175°C; !H NMR (CDCI3): δ 1.44 (d, 6H,
2 x CH3), 1.49 (s, 9H, 3 x CH3), 3.1 (t, 4H, 2 x CH2), 3.6 (t, 4H, 2 x CH2), 3.96 (s, 3H, OCH3), 4.3 (m, IH, CH), 6.98 (d, 2H, Ar-H), 7.04 (d, I H, Ar-H), 7.13 (s, IH, NH), 7.56 (d, IH, Ar-H), 7.74 (d, 2H, Ar-H), 8.89 (s, IH, Ar-H); MS (ES): m/z 478.11, C27H35N5O3 (M++1); Analysis: Calcd. C, 67.9; H, 7.39, N, 14.66. Found: C, 68.06; H, 7.61; N, 14.16. EXAMPLE 26 4-r4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenvH-piperazine-
1 -carboxylic acid tert-butyl ester
Yellow solid, yield 54%, mp 183-184°C; !H NMR (CDC13): δ 1.49 (s, 9H, 3 x CH3), 1.68-2.29 (complex, 8H, 4 x CH2), 3.10 (t, 4H, 2 x CH ), 3.61(t, 4H,
2 x CH2), 3.96 (s, 3H, OCH3), 4.29 (m, IH, CH), 6.96 (d, 2H, Ar-H, J = 8.9 Hz),
7.04 (d, IH, J = 8.9 Hz), 7.09 (s, IH, NH), 7.56 (d, IH, Ar-H, J = 8.9 Hz), 7.71 (d, 2H, Ar-H, J = 8.9 Hz), 8.89 (s, IH, Ar-H); MS (ES): m/z 504.35,
C29H37N5O3 (M++1); Analysis: Calcd.: C, 69.16; H, 7.4; N, 13.91. Found: C, 68.84, H,7.73, N, 13.58.
EXAMPLE 27 (8-Cvclopentyl-7-methoxy-quinazolin-2-yl)-(4-piperazin-l-yl-phenyl)-amine Yellow solid, yield 77%, mp 218-219°C; ΪH NMR (CDCI3): δ 1.68-2.29 (complex, 8H, 4 x CH2), 3.11 (m, 8H, 4 x CH2), 3.96 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.97 (d, 2H, Ar-H, J = 8.9 Hz), 7.04 (d, IH, J = 8.8 Hz), 7.06 (s, IH,
NH), 7.55 (d, IH, Ar-04.12, C24H29N5O (M++1); Analysis: Calcd.: C, 71.44; H, 7.24; N, 17.36. Found: C, 70.33; H, 7.86; N, 16.73.
EXAMPLE 28
l-{4-r4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl1-piperazin-l-yl)- ethanone
Light yellow solid, yield 79%, mp 197-198°C; !H NMR (CDCI3): δ 1.44
(d, 6H, 2 x CH3), 2.16 (s, 3H, COCH3) 3.15 (m, 4H), 3.65 (m, 2H), 3.80 (m, 2H),
3.97 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.98 (d, 2H, Ar-H), 7.04 (d, IH, Ar-H),
7.13 (s, IH, NH), 7.56 (d, IH, Ar-H), 7.75 (d, 2H, Ar-H), 8.89 (s, I H, Ar-H); MS (ES): m/z 420.0 C24H29N5O2 (M++1); Analysis: Calcd.: C, 68.71; H, 6.97;
N, 16.69. Found: C, 69.07; H, 7.42; N, 16.24. EXAMPLE 29
8-Isopropyl-2-phenylamino-quinazolin-7-ol
A mixture of 1 (150 mg, 0.51 mmol) and sodium thioethoxide (214 mg,
2.55 mmol) in dimethylformamide (5 mL) was heated at 150°C for 5 hours. The
solvent was removed under reduced pressure. To the residue, ice-cold water
(30 mL) was added, and the mixture was acidified with acetic acid (0.5 mL). The
product was extracted with ethyl acetate (3 x 30 mL). The combined organic
extracts were washed with brine, dried over anhydrous sodium sulfate, and concentrated. The product was purified on a column of silica gel (EtOAc:MeOH)
to give a light yellow solid, yield 70%, mp 103-104°C; H NMR(CDC13): δ 1.52
(d, 6H, 2 x CH3), 4.30 (m, IH, CH), 5.7 brs, IH, OH), 6.83 (d, IH, Ar-H,
J = 8.7 Hz), 7.06 (m, IH, Ar-H), 7.3-7.5 (s and m merged, 3H, 2 Ar-H, NH), 7.49 (d, IH, Ar-H, 8.7 Hz), 7.83 (m, 2H, Ar-H), 8.89 (s, IH, Ar-H); MS (ES): m/z
279.37, C17H17N3θ (M+). Analysis: Calcd.: C, 73.10; H, 6.13; N, 15.04. Found:
C, 73.34; H, 6.37, N, 14.72.
EXAMPLE 30
General procedure for deprotection of an N-Boc group
To a solution of N-Boc-protected compound (0.2 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid dropwise. The reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure, and to the residue was added ice-cold water (30 mL). This mixture was basified with 5% Νa2CU3 solution, then the product was extracted with chloroform (3 x 30 mL). The combined organic extracts were washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the product was purified on a column of florisil (EtOAc:MeOH).
EXAMPLE 31 (8-Isopropyl-7-methoxy-quinazoline-2-yl)-(4-piperaziny-l-yl-phenyl)-amine
Amoφhous solid, yield 84.4%. 1H NMR (CDC13): δ 1.44 (d, 6H, 2 x CH3),
3.0-3.2 (m, 8H, 4 x CH2), 3.96 (s, 3H, OCH3), 4.3 (m, IH, CH), 6.9-7.1 (2d merged, 3H, Ar-H), 7.2 (s, IH, NH), 7.55 (d, IH, Ar-H), 7.73 (d, 2H, Ar-H), 8.88 (s, IH, Ar-H); MS (ES): m/z 378.15, C22H27N5O (M++1).
EXAMPLE 32 2-Amino-l-{4-r4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyll- piperazin- 1 - yl I -ethanone
Yellow solid, yield 85%; mp 183-185°C; lH NMR (CDCl3): δ 1.44 (d, 6H, 2 x CH3), 3.15 (m, 4H), 3.52 (s, 2H), 3.55 (m, 2H, CH2), 3.83 (m, 2H), 3.97 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.98 (d, 2H, Ar-H, 8.9 Hz), 7.05 (d, IH, Ar-H, 8.9 Hz), 7.14 (s, IH, NH), 7.56 (d, IH, Ar-H, J = 8.9 Hz), 7.76 (d, 2H, Ar-H,
J = 8.9 Hz), 8.89 (s, IH, Ar-H); MS (ES): m/z 434.66 C24H30N6O2 (M+).
EXAMPLE 33
l-{4-r4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyll-piperazin-l-yl}- ethanone. Light yellow solid, yield 79%, m.p. 197-198 °C. 1H NMR (CDC13) δ: 1.44 (d, 6H,
2XCH3), 2.16 (s, 3H, COCH3) 3.15 (m, 4H), 3.65 (m, 2H), 3.80 (m, 2H), 3.97 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.98 (d, 2H, Ar-H), 7.04 (d, IH, Ar-H), 7.13 (s, IH, NH), 7.56 (d, IH, Ar-H), 7.75 (d, 2H, Ar-H), 8.89 (s, IH, Ar-H). MS (ES): m/z 420.0 C24H29N5O2 (M++l). Analysis: Calcd. C, 68.71; H, 6.97; N, 16.69. Found: C, 69.07; H, 7.42; N, 16.24. EXAMPLE 34
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperazin-l-yl-phenyl)-amine
Amoφhous solid, Yield 84.4%. Η NMR (CDC13) δ: 1.44 (d, 6H, 2XCH3), 3.0-3.2
(m, 8H, 4XCH2), 3.96 (s, 3H, OCH3), 4.3 (m, IH CH), 6.9-7.1 (2d merged, 3H, Ar-H), 7.2 (s, IH, NH), 7.55 (d, IH, Ar-H), 7.73 (d, 2H, Ar-H), 8.88 (s, IH, Ar-
H).MS (ES): m/z 378.15, C22H27N5O (M++l).
EXAMPLE 35
2-Amino-l-{4-r4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyll- piperazin- 1-yl} -ethanone
Yellow solid, yield 85%; m.p. 183-185 °C; 1H NMR (CDC13) δ: 1.44 (d, 6H,
2XCH3), 3.15 (m, 4H), 3.52 (s, 2H), 3.55 (m, 2H, CH2), 3.83 (m, 2H), 3.97 (s, 3H, OCH3), 4.30 (m, IH, CH), 6.98 (d, 2H, Ar-H, 8.9 Hz), 7.05 (d, IH, Ar-H, 8.9 Hz), 7.14 (s, IH, NH), 7.56 (d, IH, Ar-H, J=8.9 Hz), 7.76 (d, 2H, Ar-H, J=8.9 Hz), 8.89 (s, IH, Ar-H). MS (ES): m/z 434.66 C24H30N6O2 (M+).
EXAMPLE 36
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4'-methoxy-biphenyl-4-yl)-amine
Solid, yield 69%, m.p. 198-199 °C; Η NMR (CDC13) δ: 1.45 (d, 6H, 2XCH3),
3.2-3.4 (m, 8H, 4xCH2), 3.78 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 4.31 (m, IH, CH), 6.8-7.2 (complex, 8H, 7 Ar-H, NH), 7.56 (d, IH, Ar-H), 7.75 (d, 2H, Ar-H), 8.89 (s, IH, Ar-H).MS (ES): m/z 484.22 C29H33N5O2 (M++l). Analysis: Calcd. C,
72.02; H, 6.88; N, 14.48. Found: C, 71.58; H, 7.30; N, 14.29. EXAMPLE 37
r4-(3-Amino-pyrrolidin-l-yl)-phenyll-(8-isopropyl-7-methoxy-quinazolin-2-yl)- amine
Yellow solid, yield 82.3%, mp 125-127 °C, Η NMR (CDC13) δ: 1.43 (d, 6H,
2xCH3), 1.84 (m, IH), 2.3 (m, IH), 3.08 (m, IH), 3.3-3.6 (complex, 3H), 3.76 (m, IH), 3.95 (s, 3H, OCH3), 4.30 (s, IH), 6.59 (d, 2H, Ar-H, J=8.7 Hz), 6.99 (d, IH, Ar-H, J= 8.8 Hz), 7.02 (s, IH, NH), 7.52 (d, IH, Ar-H, J=8.8 Hz), 7.64 (d, 2H, Ar- H, J=8.7 Hz), 8.86 (s, IH, Ar-H). MS (ES) m/z 378.15 (MH+) C22H27N5O.
EXAMPLE 38
(3-Fluoro-4-morpholin-4-yl-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)- amine
Yellow solid, yield 65.7% , mp 202-203 °C; Η NMR (DMSO-d6) δ: 1.41 (d, 6H, 2xCH3), 2.96 (t, 4H, 2xCH2), 3.74 (t, 4H, 2XCH2), 3.95 (s, 3H, OCH3), 4.25 (m, IH, CH), 7.01 (m, IH, Ar-H), 7.24 (d, IH, Ar-H, J=8.9 Hz), 7.55 (m, IH, Ar-H),
7.78 (d, IH, Ar-H, J=8.9 Hz), 8.04 (m, IH, Ar-H), 9.12 (s, IH, Ar-H), 9.79 (s, IH, NH). MS(ES), 397.35 (MH+), C22H25FN4O2 Analysis: Calcd.: C, 66.65; H, 6.36; N, 14.13; Found: C, 66.76; H, 6.34; N, 13,96.
EXAMPLE 39
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-morpholin-4-yl-phenyl)-amine Yellow solid, yield 81.8%, mp. 187-189 °C; Η NMR (CDC13) δ: 1.44 (d, 6H,
2xCH3), 3.15 (t, 4H, 2XCH2), 3.89 (t, 4H, 2xCH2), 3.96 (s, 3H, OCH3), 4.31 (m,
IH, CH), 6.97 (d, 2H, Ar-H, J=8.9 Hz), 7.04 (d, I H, Ar-H, J=8.9 Hz), 7.12 (s, IH,
NH), 7.56 (d, IH, Ar-H, J=8.9 Hz), 7.75 (d, 2H, Ar-H, J=8.9 Hz), 8.89 (s, IH, Ar- H). MS (ES): m/z 379.18 (MH+), C22H26N4O2. Analysis: Calcd.: C, 69.82; H,
6.92; N, 14.80. Found: C, 69.95; H, 7.06; N, 14.59.
EXAMPLE 40
2-Amino-l-{4-r4-(8-cvclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyll- piperazin- 1 -yl } -ethanone
Yellow solid, yield 60%, mp 202 °C; Η NMR (CDC13) δ: 1.6-2.3 (complex, 8H,
4xCH2), 3.1 (t, 4H, 2xCH2), 3.52 (s, 2H, CH2), 3.56 (m, 2H), 3.83 (m, 2H), 3.96 (s, 3H, OCH3), 4.3 (m, IH, CH), 6.96 (d, 2H, Ar-H, J=9 Hz), 7.05 (d, IH, Ar-H, 8.9 Hz), 7.1 (s, IH, NH), 7.57 (d, IH, Ar-H, J=8.9 Hz), 7.72 (d, 2H, Ar-H, J=9 Hz), 8.9 (s, IH, Ar-H). MS (ES): m/z 461.19 (MH+) C26H32N6O2
EXAMPLE 41
r4-(3-Amino-pyrrolidin-l-yl)-phenyll-(8-cyclopentyl-7-methoxy-quinazolin-2-yl)- amine
Yellow solid, yield 83%, m.p. 220-221 °C; 'H NMR (CDC13) δ: 1.6-2.4 (complex,
10H), 3.04 (m, IH), 3.3-3.6 (m, 3H), 3.7 (m, IH), 3.95 (s, 3H, OCH3), 4.30 (m,
IH, CH), 6.58 (d, 2H, Ar-H, J=8.9 Hz), 6.98 (s, IH, NH), 7.0 (d, IH, Ar-H, J=8.8 Hz), 7.53 (d, IH, Ar-H, J=8.8 Hz), 7.61 (d, 2H, Ar-H, J=8.9 Hz), 8.86 (s, IH, Ar- H). MS (ES): m/z 404.22 (MH+) C24H29N5O. Analysis: Calcd.: Found: C, 71.44; H, 7.24; N, 17.36. Found: C, 70.75; H, 7.44; N, 17.1.
EXAMPLE 42 2-Amino-l-{4-r4-(8-cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenvn- piperazin- 1 -yl } -4-methyl-pentan- 1 -one
Yellow solid, yield 77%, m.p. 130-132 °C; 1H NMR (CDC13) δ: 0.97 (m, 6H,
2xCH3), 1.39 (m, 2H), 1.6-2.1 (m, 7H), 2.2 (m, 2H), 3.16 (m, 4H), 3.64 (m, 2H), 3.8 (m, 3H), 3.81 (s, 3H, OCH3), 4.3 (m, IH, CH), 6.96 (d, 2H, Ar-H, J=8.9 Hz), 7.05 (d, IH, Ar-H, J=8.8 Hz), 7.1 (s, IH, NH), 7.57 (d, IH, Ar-H, J=8.8 Hz), 7.72
(d, 2H, Ar-H, J=8.9 Hz), 8.9 (s, IH, Ar-H). MS (ES): m/z 517.28 (MH+) C30H40N6O2. Analysis: Calcd.: C, 69.14; H, 7.8; N, 16.27. Found: C, 69.08; H, 8.22; N, 15.96.
EXAMPLE 43
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3-fluoro-4-moφholin-4-yl-phenyl)- amine
Yellow solid, yield 50%, m.p. 252-253 °C; 1H NMR (DMSO-d6) δ: 1.6-2.2
(complex, 8H, 4xCH2), 2.95 (t, 4H, 2xCH2), 3.74 (t, 4H, 2xCH2), 3.95 (s, 3H, OCH3), 4.24 (m, IH, CH), 7.05 (m, IH, Ar-H), 7.2 (d, IH, Ar-H, J=8.9 Hz), 7.44
(m, IH, Ar-H), 7.78 (d, IH, Ar-H, J=8.9 Hz), 8.07 (m, IH, Ar-H), 9.12 (s, IH, Ar- H), 9.78 (s, IH, NH). MS (ES): m/z 423.19 (MH+) C24H27FN4O2. EXAMPLE 44
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-morpholin-4-yl-phenyl)-amine Yellow solid, yield 85%, m.p. 243-244 °C; Η NMR (DMSO-d6) δ: 1.6-2.3 (m,
8H, 4xCH2), 3.05 (t, 4H, 2xCH2), 3.75 (t, 4H, 2xCH2), 3.93 (s, 3H, OCH3), 4.24 (m, IH, CH), 6.91 (d, 2H, Ar-H, J=9 Hz), 7.19 (d, IH, Ar-H, J=8.9 Hz), 7.7-7.9
(2d merged, 3H, Ar-H), 9.06 (s, IH, Ar-H), 9.47 (s, IH, NH). MS (ES): m/z 405.2 (MH+) C24H28N4O2.
EXAMPLE 45
{ l-r4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenvn-pyrrolidin-3-yl}- carbamic acid tert-butyl ester
Yellow solid, yield 65%, m.p. 157 °C (decomp); Η NMR (CDC13) δ: 1.57 (s, 9H, 3XCH3), 1.6-2.4 (complex, 10H), 3.1-3.65 (m, 4H), 3.96 (s, 3H, OCH3), 4.2-4.4 (m, 2H), 4.75 (s, IH, CONH), 6.6 (d, 2H, Ar-H, J=8.9 Hz), 7.06 (s, IH, NH), 7.08 (d, IH, Ar-H, J=8.9 Hz), 7.54 (d, IH, Ar-H, J=8.9 Hz), 7.63 (d, 2H, Ar-H, J=8.9 Hz), 8.88 (s, IH, Ar-H). MS (ES): m/z 504.24 (MH+) C29H37N5O3.
EXAMPLE 46
(4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)-amine
Off-white solid, yield 80%, mp 169-171 °C; 'H NMR (CDC13) δ: 1.46 (d, 6H,
2xCH3), 2.33 (d, 3H, Ar-CH3, J=1.7 Hz), 3.97 (s, 3H, OCH3), 4.3 (m, I H, CH), 6.99 (m, IH, Ar-H), 7.06 (d, IH, Ar-H, J=8.9 Hz), 7.18 s, IH, NH), 7.4 (m, IH, Ar-H), 7.58 (d, IH, Ar-H, J=8.9 Hz), 7.90 (m, IH, Ar-H), 8.91 (s, IH, Ar-H). MS(ES) m/z 326.24 (MH+). Analysis: Calcd for C19H20FN3θ.l/3H2O; C, 68.86, H, 6.29, N, 12.68. Found: C, 69.21, H, 6.26, N, 12.59.
EXAMPLE 47
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperidin-l-yl-phenyl)-amine
Yellow solid, yield 72%, mp 160-161 °C; Η NMR (CDC13) δ: 1.46 (d, 6H,
2xCH3), 1.6 (m, 2H, CH2), 1.77 (m, 4H, 2xCH2), 3.0 (t, 4H, 2xCH2), 3.97 (s, 3H, OCH3), 4.31 (m, IH, CH), 6.96 (m, IH, Ar-H), 7.06 (d, IH, Ar-H, J=8.8 Hz), 7.17 (s, IH, NH), 7.25 (m, IH, Ar-H), 7.58 (d, IH, Ar-H, J=8.8 Hz), 7.93 (m, IH, Ar- H), 8.9 (s, IH, Ar-H). MS (ES): m/z 395.48 (MH+) C23H27FN4O. Analysis Calcd : C, 70.03, H, 6.9, N, 14.2; Found: C, 69.44; H,7.01 ; N, 14.06.
EXAMPLE 48 (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-fluoro-3-methyl-phenyl)-amine
Off-white solid, yield 56%, mp 208-209 °C; Η NMR (CDC13) δ: 1.6- 2.2 (complex, 8H, 4XCH2), 2.32 (d, 3H, CH3, J=1.8 Hz), 3.97 (s, 3H, OCH3), 4.36 (m, IH, CH), 6.98 (m, I H, Ar-H), 7.07 (d, IH, Ar-H, J=8.9 Hz), 7.13 (s, IH, NH),
7.44 (m, IH, Ar-H), 7.58 (d, IH, Ar-H, J=8.9 Hz), 7.82 (m, IH, Ar-H), 8.91 (s, IH, Ar-H). MS (ES): m/z 352.29 (MH+) C2,H22FN3O. Analysis: Calcd. for C21H22FN30.1/2 H2O: C, 69.98; H, 6.43; N, 11.66. Found: C, 69.62; H, 6.09; N, 11.51. EXAMPLE 49
(8-cvclopentyl-7-methoxy-quinazolin-2-yl)-(3-Fluoro-4-piperidin-l-yl-phenyl)- amine Yellow solid, yield 56%, mp 200-201 °C; Η NMR (CDC13) δ: 1.4-2.3 (complex,
14H, 7xCH2), 3.0 (t, 4H, 2xCH2), 3.96 (s, 3H, OCH3), 4.32 (m, IH, CH), 6.95 (m,
IH, Ar-H), 7.06 (d, IH, Ar-H, J=8.8 Hz), 7.16 (m, IH, Ar-H), 7.19 (s, IH, NH),
7.57 (d, IH, Ar-H, J=8.8 Hz), 7.96 (m, IH, Ar-H), 8.9 (s, IH, Ar-H). MS (ES): m/z 421.20 (MH+). C25H29FN4O. Analysis: Calcd. For C25H29FN4O.l/2 H2O; C,
69.91; H, 7.04; N, 13.04. Found: C, 69.67; H, 6.84; N, 12.79.
EXAMPLE 50 (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3-fluoro-4-piperazin-l-yl-phenyl)- amine
Yellow solid, yield 82%, mp 228-229 °C; Η NMR (CDC13) δ: 1.7-2.3 (complex,
8H, 4xCH2), 3.06 (s, 8H, 4xCH2), 3.97 (s, 3H, OCH3), 4.3 (m, IH, CH), 6.94 (m, IH, Ar-H), 7.08 (d, IH, Ar-H, J=9 Hz), 7.1-7.2 (s and m merged, 2H, NH, Ar-H),
7.58 (d, IH, Ar-H, J=9 Hz), 7.99 (m, IH, Ar-H, 8.91 (s, IH, Ar-H). MS (ES): m/z 422.24 (MH+) C24H28FN5O. Analysis calcd for C24H28FN5O.H2O; C, 65.58; H, 6.88; N, 15.93. Found: C, 65.44; H, 6.2; N, 15.57.
Table 1. IC5o values in μM
As noted above, the compounds of this invention are potent inhibitors of cyclin-dependent kinases, and accordingly, are useful in treating and preventing neurodegenerative disorders, atherosclerosis, and other cell proliferative disorders like cancer. The compounds have exhibited excellent inhibitory activity against a wide variety of cyclin-dependent kinases, all in assay systems routinely utilized to measure such activity. A typical assay, for instance, measures inhibitory activity against the cyclin D dependent kinase 4 enzyme (cdk4/D). The invention compounds of Formula I exhibited IC50 values ranging generally from 0.011 μiM to 1.75 μM. The cdk4 assay was carried out as follows. Cyclin-Dependent Kinase 4 (cdk4) Assay
Enzyme assays for IC50 determinations (Table 1 above) and kinetic evaluation were performed in 96 well filter plates (Millipore MADVN6550). The total volume was 0.1 mL containing a final concentration of 20 mM TRIS (tris[hydroxymethyl]aminomethane), at pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP containing 0.25 μCi of [32P]ATP,
20 ng of cdk4, 1 μg of retinoblastoma, and appropriate dilutions of a compound of the present invention. All components except the ATP were added to the wells, and the plate was placed on a plate mixer for 2 minutes. The reaction was started by adding [32p]ATP and the plate was incubated at 25 °C for 15 minutes. The reaction was terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate was kept at 4°C for at least 1 hour to allow the substrate to precipitate.
The wells were then washed five times with 0.2 mL of 10% TCA and 3 p incoφoration was determined with a beta plate counter (Wallac Inc., Gaithersburg, MD).
The IC50 determinations and kinetic evaluation were performed in a
96-well filter plate (Millipore MADVN6550) in a total volume of 0.1 mL of
20 mM TRIS (tris[hydroxymethyl]aminomethane), at pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 12 mM ATP containing 0.25 μCi of [32P]ATP, 20 ng of enzyme (either cdk2/cyclinE, cdk2/A, or cdc2/cyclinB), 1 μg retinoblastoma, and appropriate dilutions of the particular invention compound. All components except the ATP were added to the wells, and the plate was placed on a plate mixer for 2 minutes. The reaction was begun by addition of [32p]ATP, and the plate was incubated at 25°C for 15 minutes. The reaction was terminated by addition of 0.1 mL of 20% TCA. The plate was kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells were then washed five times with
0.2 mL of 10% TCA and 32p incoφoration determined with a beta plate counter (Wallac Inc., Gaithersburg, MD).
The IC50 values were determined using enzyme assays performed in a total volume of 0.1 mL of a solution comprising 25 mM Hepes, pH 7.4, 5 mM MgCL2, 2 mM MnCL2, 50 μM sodium vanadate, 5 to 10 ng of cdk4, and 200 μM of a substrate peptide Ala-Glu-Gly-Ser-Ala-Tyr472.Qiu.Qiu_Yai.NH2, derived from the amino acid [Try4 ' has Deen shown to be 1 of 4 tyrosines in PLC-γ that are phosphorylated by the EGF receptor tyrosine kinase (Wahl M.I., et al., J Biol. Chem., 1990;265:3944-3948), and the peptides derived from the enzyme sequence surrounding this site are excellent substrates for the enzyme], 10 μM ATP containing 1 μCi of 2] ATP and incubated for 10 minutes at room temperature.
The reaction was terminated by the addition of 2 mL of 75 mM phosphoric acid, and the contents of the reaction passed through a 2.5 cm phosphocellulose filter disc to bind the peptide. The filter was washed five times with 75 mM phosphoric acid, placed in a vial along with 5 mL of scintillation fluid (Ready gel, Beckman), and counted on a scintillation counter.
The compounds of Formula I have also exhibited good inhibitor activity against other cyclin-dependent kinase enzymes such as cdk2/cyclinE, cdk2/cyclinA, and cdk 1 /cyclinB .
When measured against cdk2/E. the invention compounds exhibited IC50 values ranging generally from about 0.004 to greater than 5 μM. Against cdk2/A, the compounds exhibited IC50 values ranging from about 0.028 to greater than
5 μM, and against cdk2/B, generally from about 0.214 to greater than5 μM. The assays were carried out as described above, and specific data is given in Table 1 above.
Cdk5/p25 Proline-directed Protein Kinase Assay Protocol
Source of enzyme: recombinant baculovirus-infected insect cell sf9 - expressed recombinant Cdk5-p25 complex
Puφose: To evaluate the ability of test agents to inhibit Cdk5/p25 phosphorylation of Histone HI. Method: Baculovirus-insect cell His-tagged Cdk5/Glu-tagged p25 (or GST-p25) enzyme complex is diluted to a concentration of 50 ng/20 μL in Enzyme Dilution Buffer (EDB - 50 mM Tris-HCl [pH 8.0], 10 mM NaCl, 10 mM MgCl , and
1 mM DTT). A 20 μL sample of test agent (diluted in EDB) is then combined with 20 μL of the of the final Cdk5/p25 enzyme preparation and allowed to stand for 5 minutes at room temperature. Twenty-five microliters of substrate solution containing 115 μL/mL Histone HI, 30 μM ATP (vanadate-free), and 30 μiCi/mL γ.33p ATP (Amersham) in EDB is then added to the test agent/enzyme preparation and shaken at 30°C for 45 minutes. A 50 μL sample of the final preparation is added to 100 mL of 150 mM phosphoric acid on ice for 30 minutes to facilitate precipitation. The precipitate is then filtered through a 96 well phosphocellucose filter plate and subsequently rinsed 3 times with 75 mM phosphoric acid. Each well then receives 20 μL of scintillation cocktail, and the plates are counted for beta emissions using a Trilux Counter (33p filter protocol). Test samples are compared to Control (no test agent present; as 0% inhibition) and
Baseline level (no enzyme, no test agent; as 100% inhibition) beta emissions to determine the percent inhibition of Histone HI phosphorylation.
The invention compounds can be formulated in conventional manners to provide convenient dosage forms for delivery to mammals by various routes, including oral, parenteral (i.e., subcutaneous, intravenous, and intramuscular), transdermal, e.g. slow release skin patch or cream, as well as by slow release delivery devices such as osmotic pumps, suppositories, and buccal seals. The following examples further illustrate how the compounds are readily formulated.
EXAMPLE 51
50 mg Tablet Formulation
Per Per 10,000
Tablet Tablets
0.050 g Example 20 g-
0.080 g Lactose 800 g
0.010 g corn starch (for mix) 100 g
0.008 g corn starch (for paste) 80 g
0.148 g 1480 g
0.002 g magnesium stearate (1 20 g
0.150 g 1500 g
The quinazoline, lactose, and corn starch (for mix) are blended to uniformity. The corn starch (for paste) is suspended in 600 mL of water and heated with stirring to form a paste. This paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are then passed through a No. 16 screen. The mixture is lubricated with 1 % magnesium stearate and compressed into tablets in a conventional tableting machine. The tablets are useful for treating cancers such as breast, prostate, lung, ovarian, colon, pancreatic, melanoma, esophageal, brain,
Kaposi's sarcoma, and lymphomas, or neurodegenerative disorders such as Alzheimer's.
EXAMPLE 52 Preparation of Oral Suspension
Ingredient Amount
Example 20 500 mg
Sorbitol solution (70% N.F.) 40 mL
Sodium benzoate 150 mg
Saccharin 10 mg
Cherry flavor 50 mg
Distilled water qs 100 mL The sorbitol solution is added to 40 mL of distilled water, and the quinazoline is suspended therein. The saccharin, sodium benzoate, and flavoring are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 5 mg of invention compound.
EXAMPLE 53
Preparation of Parenteral Solution
In a solution of 700 mL of propylene glycol and 200 mL of water for injection is suspended 20.0 g of Example 20 with stirring. After suspension is complete, the pH is adjusted to 5.5 with hydrochloric acid, and the volume is made up to 1000 mL with water for injection. The formulation is sterilized, filled into 5.0 mL ampoules, each containing 2.0 mL (representing 40 mg of invention compound) and sealed under nitrogen.
EXAMPLE 54 Suppositories A mixture of 400 mg of Example 20, and 600 mg of theobroma oil is stirred at 60°C to uniformity. The mixture is cooled and allowed to harden in a tapered mold to provide a 1 g suppository.
EXAMPLE 55 Slow Release Formulation Five hundred milligrams of Example 20 is converted to a hydrochloride salt and placed into an Oros osmotic pump for controlled release for treatment of atherosclerosis.
EXAMPLE 56 Skin Patch Formulation Fifty milligrams of Example 20 is admixed with 50 mg of propylene glycol monolaurate in a polydimethylsiloxane adhesive. The mixture is layered onto an elastic film made with an adhesive formulation of polybutene, polyisobutylene, and propylene glycol monolaurate. The layers are placed between 2 layers of polyurethane film. A release liner is attached to the adhesive surface, and is removed prior to application to a skin surface. The propylene glycol monolaurate serves as a permeation-enhancing agent.

Claims

CLAIMS What is claimed is:
1. A compound of Formula I:
wherein,
R1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl,or heterocycloalkyl; R2 is OH, alkyloxy, aryloxy, or NR3R4;
A is N, or CW3; R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH2)nAr, cycloalkyl, heterocycloalkyl, or heteroaryl, or R and R4 together with the nitrogen to which they are attached optionally may form a ring having 3 to 7 carbon atoms and said ring optionally contains 1 , 2 or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur including S(O) and S(O)2. Said ring also may be additionally substituted with up to 3 groups selected from alkyl, haloalkyl, NR8C(O)R9, C(O)OR8, C(O)R8, C(O)NR8R9, NR8R9, NR8SO2R9, OR8 , SO2NR3R4, or SR8;
W1 and W are independently xτr 3r NR>JR>44Rn 8δ-Xι , OR', SR3, hydrogen, halogen, haloalkyl, COR3, CO2R3, CONR3R4, S(O)R3,
SO2R3, SO2NR3R4, SO3R3, P(O)(OR3)2, aldehyde, nitrile, nitro, alkyl,
T(CH2)mQR8, C(O)T(CH2)mQR8, or T(CH2)mCO2R8 where m is 1-6, T is
O, S, NR3, N(O)R3, NR3R4X, or CR3R4, and Q is O, S, NR9, N(O)R9 or NR9R' °X, or NR9C(O)T(CH2)mQR9;
R5 is hydrogen, or alkyl;
R6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR3, CO2R3,
CONR3R4, SO2NR3R4, SO2R3, SO3R3, P(O)(OR3)2, aldehyde, nitrile, nitro,
OR3, or NR3R4 W3 is NR3R4, N(O)R3R4, NR3R4R8X, OH, OR3, SH, SR3, halogen, COR3, CO2R3,
CONR3R4, S(O)R3, SO2R3, SO2NR3R4, SO3R3, (CH2)nP(O)(OR3)2,
NR3SO2R4, aldehyde, nitrile, nitro, alkyl, T(CH2)mQR8, C(O)T(CH2)mQR8,
NR8C(O)T(CH2)mQRπ, or T(CH2)mCO2R3 where m and n are independently 1-6, T is O, S, NR3, N(O)R3, NR3R4W, or CR3R4, and Q is O, S, NR9, N(O)R9 or NR9R,0X;
R8, R9, R10 and Ru are hydrogen, alkyl, or aryl;
X is a halogen; or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof.
2. A compound of Claim 1 wherein R1 is alkyl.
3. A compound of Claim 1 wherein R1 is isopropyl.
4. A compound of Claim 1 wherein R1 is cycloalkyl.
5. A compound of Claim 1 wherein R1 is cyclopentyl.
6. A compound of Claim 1 wherein R2 is hydroxy.
7. A compound of Claim 1 wherein R is alkyloxy.
8. A compound ofClaim wherein R is methoxy.
9. A compound ofClaim wherein R2 is NR3R4.
10. A compound ofClaim wherein A is CW3.
11. A compound ofClaim wherein W3 is piperidine.
12. A compound ofClaim wherein W3 is substituted piperidine.
13. A compound ofClaim wherein W3 is pyrolidine.
14. A compound ofClaim wherein W3 is substituted pyrolidine.
15. A compound ofClaim wherein W is piperazine.
16. A compound ofClaim wherein W is substituted piperazine
17. A compound ofClaim wherein W3 is hydrogen,
18. A compound ofClaim wherein W2 and W3 are hydrogen,
19. A compound ofClaim wherein R5 is hydrogen,
20. A compound ofClaim wherein R5 is alkyl.
21. A compound ofClaim wherein R6 is hydrogen,
22. A compound ofClaim wherein R is alkyl.
23. A compound ofClaim wherein W^, W2, and W3 are hydrogen.
24. A compound ofClaim wherein wherein R^ and R^ are hydrogen.
25. A compound ofClaim wherein wherein W , W2, and W3 are hydrogen, and R! is alkyl.
26. A compound of Claim wherein wherein W', W2, and W3 are hydrogen, and R! is cycloalkyl.
27. A compound of Claim wherein wherein W3 is piperidine or substituted piperidine, and R* is alkyl or cycloalkyl.
28. A compound of Claim wherein W3 is pyrrolidine or substituted pyrrolidine, and R is a kyl or cycloalkyl.
29. A compound of Claim wherein W3 is piperazine or substituted piperazine, and R s a kyl or cycloalkyl.
30. A compound of Claim wherein W-> is piperidine or substituted piperidine, R2 is alkyloxy, and R^ is alkyl or cycloalkyl.
31. A compound of Claim 1 wherein wherein W3 is pyrrolidine or substituted pyrrolidine, R2 is alkyloxy, and RHs alkyl or cycloalkyl.
32. A compound of Claim 1 wherein W3 is piperazine or substituted piperazine, R2 is alkyloxy, and R^ is alkyl or cycloalkyl.
33. A compound selected from:
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-phenyl-amine;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-phenyl-amine;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperidin- 1 -yl- phenyl)-amine; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin- 1 -yl- phenyl)-amine;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-piperidin- 1 -yl- phenyl)-amine;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin- 1 -yl- phenyl)-amine;
8-Isopropyl-2-phenylamino-quinazolin-7-ol;
4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazine-1 -carboxylic acid tert-butyl ester;
4- [4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl] - piperazine- 1 -carboxylic acid tert-butyl ester;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-piperazin-l-yl- phenyl)-amine;
8-Cyclopentyl-2-(4-piperazin-l-yl-phenylamino)-quinazolin-7-ol;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2- y lamino)-phenyl] -piperazin- 1 -y 1 } -ethanone ;
8-Isopropyl-2-(4-piperazin- 1 -yl-phenylamino)-quinazolin-7-ol; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-piperazin- 1 -yl- phenyl)-amine;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl } -ethanone;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)- phenyl]-piperazin- 1 -yl } -ethanone; 2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-quinazolin-2-ylamino)- phenyl]-piperazin- 1 -yl } -ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2- ylamino)-phenyl]-piperazin- 1-yl} -4-methyl-pentan- 1 -one; 2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl} -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino- 1 -{4-[4-(7-hydroxy-8-isopropyl-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
N-(4-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -4-oxo-butyl)-acetamide;
N-(4-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)- phenyl]-piperazin- 1 -yl} -4-oxo-butyl)-acetamide; N-(4-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl} -4-oxo-butyl)-acetamide;
N-(4-{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)- phenylj-piperazin- 1 -yl} -4-oxo-butyl)-acetamide;
8-Isopropyl-2-(pyridin-4-ylamino)-quinazolin-7-ol; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-pyridin-4-yl-amine;
(8-cyclopentyl-7-methoxy-quinazolin-2-yl)-pyridin-4-yl-amine; 8-cyclopentyl-2-(pyridin-4-ylamino)-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)- [4-(5 -methyl- hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine; 8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2- yl)-phenylamino]-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-quinazolin-7-ol;
[4-(3 -Amino-pyrrolidin- 1 -yl)-phenyl] -(8 -cy clopentyl-7-methoxy- quinazolin-2-yl)-amine; 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl- quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-isopropyl-7-methoxy- quinazolin-2-yl)-amine; 2-[4-(3-Amino-pyrrolidin-l -yl)-phenylamino]-8-isopropyl- quinazolin-7-ol;
(4-Fluoro-3 -trifluoromethyl -phenyl)-(8-isopropyl-7-methoxy- quinazolin-2-yl)-amine;
2-(4-Fluoro-3-trifluoromethyl-phenylamino)-8-isopropyl- quinazolin-7-ol;
(4-Fluoro-3-trifluoromethyl-phenyl)-(8-cyclopentyl-7-methoxy- quinazolin-2-yl)-amine;
2-(4-Fluoro-3-trifluoromethyl-phenylamino)-8-cyclopentyl- quinazolin-7-ol; N-{ l-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)- phenyl]-pyrrolidin-3-yl} -acetamide;
N-{ 1 -[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)- pheny 1] -pyrrolidin-3 -yl } -acetamide;
N-{ l-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- pyrrolidin-3-yl} -acetamide;
N-{l-[4-(8-Isopropyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- pyrrolidin-3-yl} -acetamide; l-{4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl} -ethanone; l-{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -ethanone ;
{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-pyrrolidin-2-yl-methanone;
{4-[4-(8-Cyclopentyl-7-Hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin-l-yl}-pyrrolidin-2-yl-methanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl} -ethanone; l-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin-1 -yl} -ethanone;
{4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl} -pyrrolidin-2-yl-methanone; { 4- [4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl] - piperazin- 1 -yl } -pyrrolidin-2-yl-methanone;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-quinazolin-2-ylamino)- phenyl]-piperazin- 1 -yl } -propan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-quinazolin-2-ylamino)- phenyl]-piperazin- 1 -yl } -propan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl} -propan- 1 -one;
2-Amino- 1 - {4-[4-(8-cyclopentyl-7-hydroxy-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl} -propan- 1 -one; 1 -{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Isopropyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- piperazin-1-yl}-propan-1-one; l-{4-[4-(7-Hydroxy-8-isopropyl-quinazolin-2-ylamino)-phenyl]- piperazin-1-yl}-propan-1-one;
8-Isopropyl-2-phenylamino-5,6-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-phenyl- amine;
8-Isopropyl-2-phenylamino-5,8-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-phenyl- amine;
8-Cyclopentyl-2-phenylamino-5,6-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-phenyl- amine;
8-Cyclopentyl-2-phenylamino-5,8-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-phenyl- amine;
8-Isopropyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,6-dihydro- quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4- pyrrolidin- 1 -yl-phenyl)-amine;
8-Isopropyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,8-dihydro- quinazolin-7-ol;
(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4- pyrrolidin-l-yl-phenyl)-amine;
8-Cyclopentyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,6-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4- pyrrolidin- 1 -yl-phenyl)-amine; 8-Cyclopentyl-2-(4-pyrrolidin-l-yl-phenylamino)-5,8-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4- pyrrolidin- 1 -yl-phenyl)-amine;
8-Isopropyl-2-(4-piperazin-l-yl-phenylamino)-5,6-dihydro- quinazolin-7-ol;
(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-piperazin- 1 -yl-phenyl)-amine;
8-Isopropyl-2-(4-piperazin-l-yl-phenylamino)-5,8-dihydro- quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-piperazin-
1 -yl-phenyl)-amine;
8-Cyclopentyl-2-(4-piperazin-l-yl-phenylamino)-5,6-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4- piperazin- l-yl-phenyl)-amine;
8-Cyclopentyl-2-(4-piperazin-l-yl-phenylamino)-5,8-dihydro- quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4- piperazin- 1 -yl-phenyl)-amine;
2-(4-Fluoro-3-methyl-phenylamino)-8-isopropyl-5,6-dihydro- quinazolin-7-ol; (4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-5,6-dihydro- quinazolin-2-yl)-amine;
2-(4-Fluoro-3-methyl-phenylamino)-8-isopropyl-5,8-dihydro- quinazolin-7-ol;
(4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-5,8-dihydro- quinazolin-2-yl)-amine;
8-Cyclopentyl-2-(4-fluoro-3-methyl-phenylamino)-5,6-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-(4-fluoro- 3-methyl-phenyl)-amine; 8-Cyclopentyl-2-(4-fluoro-3-methyl-phenylamino)-5,8-dihydro- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-(4-fluoro- 3-methyl-phenyl)-amine;
8-Isopropyl-2-(pyridin-4-ylamino)-5,6-dihydro-quinazolin-7-ol; (8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-pyridin-4-yl- amine;
8-Isopropyl-2-(pyridin-4-ylamino)-5 , 8 -dihydro-quinazolin-7-ol ; (8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-pyridin-4-yl- amine; 8-Cyclopentyl-2-(pyridin-4-ylamino)-5,6-dihydro-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-pyridin-4- yl-amine;
8-Cyclopentyl-2-(pyridin-4-ylamino)-5,8-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-pyridin-4- yl-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-isopropyl-5,6- dihydro-quinazolin-7-ol; [4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-isopropyl-7-methoxy-5,6- dihydro-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-isopropyl-5,8- dihydro-quinazolin-7-ol; [4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-isopropyl-7-methoxy-5,8- dihydro-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl-5,6- dihydro-quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-cyclopentyl-7-methoxy- 5,6-dihydro-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl-5,8- dihydro-quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-phenyl]-(8-cyclopentyl-7-methoxy- 5,8-dihydro-quinazolin-2-yl)-amine; 8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-5,6-dihydro-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-[4-(5- methyl-hexahydro-pyrrolo [3 ,4-c]pyrrol-2-yl)-phenyl] -amine;
8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-5,8-dihydro-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-[4-(5- methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2- yl)-phenylamino]-5,6-dihydro-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2-yl)-[4-(5- methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Cyclopentyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2- yl)-phenylamino]-5,8-dihydro-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2-yl)-[4-(5- methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine; l-{4-[4-(7-Hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1-yl} -ethanone; l-{4-[4-(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone; l-{4-[4-(7-Hydroxy-8-isopropyl-5,8-dihydro-quinazolin-2- y lamino)-pheny 1] -piperazin- 1 -y 1 } -ethanone ; l-{4-[4-(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -ethanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl } -ethanone; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2- y lamino)-pheny 1] -piperazin- 1 -y 1 } -ethanone ; l-{4-[4-(7-Hydroxy-8-isopropyl-5,6-dihydro-quinazolin-2- ylamino)-phenyl]-piperazin- 1 -yl}-propan- 1 -one; l-{4-[4-(8-Isopropyl-7-methoxy-5,6-dihydro-quinazolin-2- y lamino)-phenyl] -piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(7-Hydroxy-8-isopropyl-5,8-dihydro-quinazolin-2- y lamino)-phenyl] -piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Isopropyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,6-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -y 1 } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5,8-dihydro-quinazolin-2- y lamino)-pheny l]-piperazin- 1 -yl } -propan- 1 -one; l-{4-[4-(8-Cyclopentyl-7-methoxy-5,8-dihydro-quinazolin-2- ylamino)-phenyl] -piperazin- 1 -yl} -propan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,6-dihydro-quinazolin- 2-ylamino)-phenyl]-piperazin-l-yl}-3-methyl-butan-l-one; 2-Amino-l -{4-[4-(8-isopropyl-7-methoxy-5,6-dihydro-quinazolin- 2-ylamino)-pheny 1] -piperazin- 1 -y 1 } -3 -methy 1-butan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,8-dihydro-quinazolin- 2-ylamino)-phenyl]-piperazin- 1 -yl } -3-methyl-butan- 1 -one; 2-A_mino-l-{4-[4-(8-isopropyl-7-methoxy-5,8-dihydro-quinazolin-
2-ylamino)-phenyl] -piperazin- 1 -yl } -3-methyl-butan- 1 -one;
2- Amino- 1 - { 4- [4-(8-cyclopentyl-7-hydroxy-5 ,6-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin-l-yl}-3-methyl-butan-l-one; 2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,6-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin-l -yl} -3 -methy 1-butan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,8-dihydro- quinazolin-2-ylamirio)-phenyl]-piperazin- 1 -yl} -3-methyl-butan- 1 -one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,8-dihydro- quinazolin-2-ylamino)-phenyl] -piperazin- 1 -yl} -3-methyl-butan- 1 -one; 2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,6-dihydro-quinazolin-
2-ylamino)-phenyl] -piperazin- 1 -yl} -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,6-dihydro-quinazolin- 2-ylamino)-phenyl] -piperazin- 1 -yl} -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,8-dihydro-quinazolin- 2-ylamino)-phenyl] -piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,8-dihydro-quinazolin- 2-ylamino)-phenyl]-piperazin- 1 -yl} -4-methyl-pentan- 1 -one;
2- Amino- 1 - { 4- [4-(8-cyclopentyl-7-hydroxy-5 ,6-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin-l-yl}-4-methyl-pentan-l-one; 2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,6-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin-l-yl}-4-methyl-pentan-l-one;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,8-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin- 1 -yl } -4-methyl-pentan- 1 -one; 2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,8-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin- 1 -yl } -4-methyl-pentan- 1 -one;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,6-dihydro-quinazolin- 2-ylamino)-phenyl]-piperazin- 1-yl} -ethanone; 2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,6-dihydro-quinazolin- 2-ylamino)-phenyl]-piperazin- 1 -yl} -ethanone;
2-Amino-l-{4-[4-(7-hydroxy-8-isopropyl-5,8-dihydro-quinazolin- 2-ylamino)-phenyl]-piperazin- 1-yl} -ethanone; 2-Amino-l-{4-[4-(8-isopropyl-7-methoxy-5,8-dihydro-quinazolin-
2-ylamino)-pheny l]-piperazin- 1 -yl } -ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,6-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin-l-yl}-ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,6-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin-l -yl} -ethanone;
2-Amino-l-{4-[4-(8-cyclopentyl-7-hydroxy-5,8-dihydro- quinazolin-2-ylamino)-phenyl] -piperazin- 1-yl} -ethanone;
2-A_mino-l-{4-[4-(8-cyclopentyl-7-methoxy-5,8-dihydro- quinazolin-2-ylamino)-phenyl]-piperazin- 1 -yl} -ethanone; (4-Fluoro-3-methyl-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2- yl)-amine;
2-(4-Fluoro-3-methyl-phenylamino)-8-isopropyl-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-fluoro-3-methyl- phenyl)-amine; 8-Cyclopentyl-2-(4-fluoro-3-methyl-phenylamino)-quinazolin-7-ol;
(3-Chloro-4-fluoro-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2- yl)-amine;
2-(3 -Chloro-4-fluoro-phenylamino)-8-isopropyl-quinazolin-7-ol ; (3-Chloro-4-fluoro-phenyl)-(8-cyclopentyl-7-methoxy-quinazolin- 2-yl)-amine;
2-(3-Chloro-4-fluoro-phenylamino)-8-cyclopentyl-quinazolin-7-ol; (3,4-Difluoro-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)- amine;
2-(3,4-Difluoro-phenylamino)-8-isopropyl-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3,4-difluoro-phenyl)- amine;
8-Cyclopentyl-2-(3,4-difluoro-phenylamino)-quinazolin-7-ol; (3-Fluoro-4-piperazin- 1 -yl-phenyl)-(8-isopropyl-7-methoxy- quinazolin-2-yl)-amine;
2-(3-Fluoro-4-piperazin-l-yl-phenylamino)-8-isopropyl- quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3-fluoro-4-piperazin-
1 -yl-phenyl)-amine;
8-Cyclopentyl-2-(3-fluoro-4-piperazin- 1 -yl-phenylamino)- quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenyl]-(8-isopropyl-7- methoxy-quinazolin-2-yl)-amine;
2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]-8- isopropyl-quinazolin-7-ol;
[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenyl]-(8-cyclopentyl-7- methoxy-quinazolin-2-yl)-amine; 2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]-8- cyclopentyl-quinazolin-7-ol;
{ 3 -Fluoro-4- [4-(3 -moφholin-4-yl-propyl)-piperidin- 1 -yl] -phenyl } - (8-isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2- { 3 -Fluoro-4- [4-(3 -moφholin-4-yl-propyl)-piperidin- 1 -yl] - phenylamino}-8-isopropyl-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-{3-fluoro-4-[4-(3- moφholin-4-yl-propyl)-piperidin-l-yl]-phenyl}-amine;
8-Cyclopentyl-2- { 3 -fluoro-4- [4-(3 -moφholin-4-yl-propy 1)- piperidin-l-yl]-phenylamino}-quinazolin-7-ol; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-moφholin-4-yl- propyl)-piperidin- 1 -yl] -phenyl } -amine;
8-Isopropyl-2-{4-[4-(3-moφholin-4-yl-propyl)-piperidin-l-yl]- phenylamino}-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-moφholin-4- y l-propyl)-piperidin- 1 -yl] -phenyl } -amine;
8-Cyclopentyl-2-{4-[4-(3-moφholin-4-yl-propy_)-piperidin-l-yl]- phenylamino } -quinazolin-7-ol ; (8-Isopropyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-piperazin- 1 -yl- propy l)-piperidin- 1 -yl] -phenyl } -amine;
8-Isopropyl-2- {4-[4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl]- phenylamino}-quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-{4-[4-(3-piperazin-l- yl-propyl)-piperidin-l-yl]-phenyl}-amine;
8-Cyclopentyl-2- {4- [4-(3 -piperazin- 1 -yl-propy l)-piperidin- 1 -yl] - phenylamino } -quinazolin-7-ol ;
{ 3 -Chloro-4- [4-(3 -piperazin- 1 -yl-propy l)-piperidin- 1 -y l]-phenyl } - (8-isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2- { 3 -Chloro-4-[4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl] - phenylamino}-8-isopropyl-quinazolin-7-ol;
{ 3 -Chloro-4- [4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl]-phenyl } - (8-cyclopentyl-7-methoxy-quinazolin-2-yl)-amine; 2- { 3 -Chloro-4- [4-(3 -piperazin- 1 -yl-propyl)-piperidin- 1 -yl] - phenylamino }-8-cyclopentyl-quinazolin-7-ol;
(3-Fluoro-4-{4-[3-(lH-tetrazol-5-yl)-propyl]-piperidin-l-yl}- phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2-(3 -Fluoro-4- {4- [3 -( 1 H-tetrazol-5 -yl)-propyl] -piperidin- 1 -y 1 } - phenylamino)-8-isopropyl-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(3-fluoro-4-{4-[3-(lH- tetrazol-5-yl)-propyl]-piperidin-l -yl}-phenyl)-amine;
8-Cyclopentyl-2-(3-fluoro-4-{4-[3-(lH-tetrazol-5-yl)-propyl]- piperidin- 1 -yl } -phenylamino)-quinazolin-7-ol ; (4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -y l)-propyl] -piperidin- 1 -y 1 } -3 - chloro-phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl] -piperidin- 1 -yl } -3 - chloro-phenylamino)-8-isopropyl-quinazolin-7-ol;
(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -yl } -3 - chloro-phenyl)-(8-cyclopentyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -yl } -3 - chloro-phenylamino)-8-cyclopentyl-quinazolin-7-ol; (4- {4- [3 -(3 -Amino-pyrrolidin- 1 -y l)-propy 1] -piperidin- 1 -yl } - phenyl)-(8-isopropyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- {4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -yl} - phenylamino)-8-isopropyl-quinazolin-7-ol; (4- {4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl] -piperidin- 1 -yl } - phenyl)-(8-cyclopentyl-7-methoxy-quinazolin-2-yl)-amine;
2-(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -yl } - phenylamino)-8-cyclopentyl-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-{4-[4-(4-methoxy- phenyl)-piperazin-l -yl]-phenyl}-amine;
8-Isopropyl-2-{4-[4-(4-methoxy-phenyl)-piperazin-l-yl]- phenylamino}-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)- {4- [4-(4-methoxy- phenyl)-piperazin- 1 -yl]-phenyl } -amine; 8-Cyclopentyl-2-{4-[4-(4-methoxy-phenyl)-piperazin-l-yl]- phenylamino}-quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-[4-(3,3,4-trimethyl- piperazin- 1 -yl)-phenyl]-amine;
8-Isopropyl-2-[4-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)- phenylamino]-quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl- hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine;
8-Cyclopentyl-2- [4-(5 -methyl-hexahydro-pyrrolo [3 ,4-c] pyrrol-2- yl)-phenylamino]-quinazolin-7-ol; 8-Isopropyl-2-[4-(3,3,4-trimethyl-piperazin-l-yl)-phenylamino]- quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(3,3,4-trimethyl- piperazin- 1 -yl)-phenyl]-amine;
8-Cyclopentyl-2-[4-(3,3,4-trimethyl-piperazin-l -yl)-phenylamino]- quinazolin-7-ol;
(8-Isopropyl-7-methoxy-quinazolin-2-yl)-[4-(5-methyl-hexahydro- pyrrolo[3,4-c]pyrrol-2-yl)-phenyl]-amine; (8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-perhydro- 1 ,4- diazepin- 1 -yl-phenyl)-amine;
8-Cyclopentyl-2-(4-perhydro- 1 ,4-diazepin- 1 -yl-phenylamino)- quinazolin-7-ol; 2-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]-
2,6-dimethyl-piperazin- 1 -yl} -ethanol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(2-methylamino- ethoxy)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-methoxy-quinazolin-2-ylamino)-phenyl]- perhydro- 1 ,4-diazepin- 1 -yl} -ethanone;
8-Cyclopentyl-2- [4-(3 ,3 -dimethyl-piperazin- 1 -yl)-phenylamino] - quinazolin-7-ol;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-[4-(3,3-dimethyl- piperazin- 1 -yl)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-hydroxy-quinazolin-2-ylamino)-phenyl]- perhydro- 1 ,4-diazepin- 1 -yl } -ethanone;
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(4-{4-[3-(lH-tetrazol- 5 -yl)-propyl] -piperidin- 1 -y 1 } -phenyl)-amine;
8-Cyclopentyl-2-(4- {4- [3 -( 1 H-tetrazol-5 -yl)-propyl] -piperidin- 1 - yl}-phenylamino)-quinazolin-7-ol;
8-Cyclopentyl-N2-(4-piperazin- 1 -yl-phenyl)-quinazoline-2,7- diamine;
8-Cyclopentyl-N2-[4-(4-methyl-piperazin-l-yl)-phenyl]- quinazoline-2,7-diamine; l-{4-[4-(7-Amino-8-cyclopentyl-quinazolin-2-ylamino)-phenyl]- piperazin- 1 -y 1 } -ethanone;
8-Cyclopentyl-N2-(4-perhydro- 1 ,4-diazepin- 1 -yl-phenyl)- quinazoline-2 , 7-diamine ;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]- quinazoline-2,7-diamine;
8-Cyclopentyl-N7-methyl-N2-(4-piperazin- 1 -yl-phenyl)- quinazoline-2, 7-diamine; 8-Cyclopentyl-N7-methyl-N2-[4-(4-methyl-piperazin-l-yl)- phenyl]-quinazoline-2, 7-diamine; l-{4-[4-(8-Cyclopentyl-7-methylamino-quinazolin-2-ylamino)- phenyl]-piperazin-l-yl}-ethanone; 8-Cyclopentyl-N7-methyl-N2-(4-perhydro- 1 ,4-diazepin- 1 -yl- phenyl)-quinazoline-2, 7-diamine;
8-Cyclopenty 1-N2- [4-(3 ,3 -dimethyl-piperazin- 1 -yl)-phenyl] -N7- methyl-quinazoline-2,7-diamine;
8-Cyclopentyl-N7,N7-dimethyl-N2-(4-piperazin- 1 -yl-phenyl)- quinazoline -2, 7-diamine;
8-Cyclopentyl-N7,N7-dimethyl-N -[4-(4-methyl-piperazin-l-yl)- phenyl]-quinazoline-2,7-diamine; l-{4-[4-(8-Cyclopentyl-7-dimethylamino-quinazolin-2-ylamino)- phenyl] -piperazin- 1 -yl } -ethanone; 8-Cyclopentyl-N7,N7-dimethyl-N -(4-perhydro-l,4-diazepin-l-yl- phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-
N7,N7-dimethyl-quinazoline-2,7-diamine;
8-Cyclopentyl-N -(4-{4-[3-(lH-tetrazol-5-yl)-propy_]-piperidin-l- yl}-phenyl)-quinazoline-2, 7-diamine;
8-Cyclopentyl-N7-methyl-N2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]- piperidin-l-yl}-phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-{4-[4-(3-piperazin-l-yl-propyl)-piperidin-l-yl]- phenyl}-quinazoline-2,7-diamine; 8-Cyclopentyl-N7-methyl-N2- { 4- [4-(3 -piperazin- 1 -yl-propyl)- piperidin-l-yl]-phenyl}-quinazoline-2,7-diamine;
8-Cyclopentyl-N7,N7-dimethyl-N2- { 4- [4-(3 -piperazin- 1 -yl- propyl)-piperidin- 1 -yl] -phenyl } -quinazoline-2,7-diamine;
(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-(4-perhydro- l,4-diazepin-l-yl-phenyl)-amine; 8-Cyclopentyl-5-methyl-2-(4-perhydro- 1 ,4-diazepin- 1 -yl- phenylamino)-quinazolin-7-ol;
2-{4-[4-(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2- ylamino)-phenyl]-2,6-dimethyl-piperazin- 1-yl} -ethanol; (8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-[4-(2- methylamino-ethoxy)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2- ylamino)-phenyl]-perhydro-l,4-diazepin-l-yl}-ethanone;
8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)-phenylamino]-5- methyl-quinazolin-7-ol;
(8-Cyclopenty l-7-methoxy-5 -methyl-quinazolin-2-y 1)- [4-(3 ,3 - dimethyl-piperazin- 1 -yl)-phenyl]-amine; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5-methyl-quinazolin-2- ylamino)-phenyl]-perhydro- 1 ,4-diazepin- 1 -yl } -ethanone; (8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-(4-{4-[3-
(lH-tetrazol-5-yl)-propyl]-piperidin-l-yl}-phenyl)-amine;
8-Cyclopentyl-5-methyl-2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]- piperidin-l-yl}-phenylamino)-quinazolin-7-ol; l-{4-[4-(8-Cyclopentyl-7-hydroxy-5-methyl-quinazolin-2- ylamino)-phenyl] -piperazin- 1-yl} -ethanone; l-{4-[4-(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone;
8-Cyclopentyl-5-methyl-2-(4-piperazin- 1 -yl-phenylamino)- quinazolin-7-ol; (8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-(4-piperazin-
1 -yl-phenyl)-amine;
(8-Cyclopentyl-7-methoxy-5-methyl-quinazolin-2-yl)-{4-[4-(3- piperazin-1 -yl-propyl)-piperidin- 1 -yl] -phenyl} -amine;
8-Cyclopentyl-5-methyl-2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin- l-yl]-phenylamino}-quinazolin-7-ol;
8-Cyclopentyl-5-methyl-N -(4-piperazin-l-yl-phenyl)-quinazoline- 2, 7-diamine; 8-Cyclopentyl-5 -methyl-N2- [4-(4-methy 1-piperazin- 1 -y l)-phenyl] - quinazoline-2, 7-diamine; l-{4-[4-(7-Amino-8-cyclopentyl-5-methyl-quinazolin-2-ylamino)- phenylj-piperazin- 1 -yl} -ethanone; 8-Cyclopentyl-5-methyl-N -(4-perhydro-l,4-diazepin-l-yl- phenyl)-quinazoline-2, 7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-5- methyl-quinazoline-2,7-diamine;
8-Cyclopentyl-5,N7-dimethyl-N2-(4-piperazin-l-yl-phenyl)- quinazoline-2, 7-diamine;
8-Cyclopentyl-5,N7-dimethyl-N2-[4-(4-methyl-piperazin-l-yl)- phenyl]-quinazoline-2,7-diamine; l-{4-[4-(8-Cyclopentyl-5-methyl-7-methylamino-quinazolin-2- ylamino)-pheny 1] -piperazin- 1 -yl } -ethanone; 8-Cyclopentyl-5,N7-dimethyl-N2-(4-perhydro- 1 ,4-diazepin- 1 -yl- phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-5,N7- dimethyl-quinazoline-2,7-diamine;
8-Cyclopentyl-5,N7,N7-trimethyl-N2-(4-piperazin- 1 -yl-phenyl)- quinazoline-2,7-diamine;
8-Cyclopentyl-5 ,N7,N7-trimethyl-N2- [4-(4-methy 1-piperazin- 1 - yl)-phenyl]-quinazoline-2, 7-diamine; l-{4-[4-(8-Cyclopentyl-7-dimethylamino-5-methyl-quinazolin-2- ylamino)-phenyl]-piperazin-l-yl}-ethanone; 8-Cyclopentyl-5,N7,N7-trimethyl-N -(4-perhydro-l ,4-diazepin-l - yl-phenyl)-quinazoline-2,7-diamine;
8-Cyclopentyl-N2-[4-(3,3-dimethyl-piperazin-l-yl)-phenyl]-
5,N7,N7-trimethyl-quinazoline-2, 7-diamine;
8-Cyclopentyl-5-methyl-N2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]- piperidin-l-yl}-phenyl)-quinazoline-2, 7-diamine; 8-Cyclopentyl-5,N7-dimethyl-N2-(4-{4-[3-(lH-tetrazol-5-yl)- propyl] -piperidin- 1 -yl } -phenyl)-quinazoline-2, 7-diamine;
8-Cyclopentyl-5-methyl-N -{4-[4-(3-piperazin-l-yl-propyl)- piperidin-l-yl]-phenyl}-quinazoline-2,7-diamine;
8-Cyclopentyl-5,N7-dimethyl-N2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin- 1 -yl]-phenyl} -quinazoline-2,7-diamine; and
8-Cyclopentyl-5,N7,N7-trimethyl-N2-{4-[4-(3-piperazin-l-yl- propyl)-piperidin-l-yl]-phenyl}-quinazoline-2, 7-diamine.
34. A compound of Formula II:
wherein, the dotted line represents a bond at the C5-C6, C6-C7, or C7-C8 position. R1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl,or heterocycloalkyl;
R2 is OH, alkyloxy, aryloxy, or NR3R4;
A is N, or CW3;
R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH )nAr, cycloalkyl, heterocycloalkyl, or heteroaryl, or R3 and R4 together with the nitrogen to which they are attached optionally may form a ring having 3 to 7 carbon atoms and said ring optionally contains 1 , 2 or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur including S(O) and S(O) . Said ring also may be additionally substituted with up to 3 groups selected from alkyl, haloalkyl,
NR8C(O)R9, C(O)OR8, C(O)R8, C(O)NR8R9, NR8R9, NR8SO2R9, OR8 , SO NR R4, or SR8;
W1 and W2 are independently selected from NR3R4, N(O)R3R4, NR3R4R8X, OR3, SR3, hydrogen, halogen, haloalkyl, COR3, CO2R3, CONR3R4, S(O)R3, SO2R3, SO2NR R4, SO3R3, P(O)(OR3)2, aldehyde, nitrile, nitro, alkyl, T(CH2)mQR8, C(O)T(CH2)mQR8, or T(CH2)mCO2R8 where m is 1-6, T is O, S, NR3, N(O)R3, NR3R4X, or CR R4, and Q is O, S, NR9, N(O)R9 or
NR9R10X, or NR9C(O)T(CH2)mQR9;
R5 is hydrogen, or alkyl;
R6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR3, CO2R3,
CONR3R4, SO2NR3R4, SO2R3, SO3R3, P(O)(OR )2, aldehyde, nitrile, nitro, OR3, or NR3R4
W3 is NR3R4, N(O)R3R4, NR3R4R8X, OH, OR3, SH, SR3, halo, COR3, CO2R3, CONR3R4, S(O)R3, SO2R3, SO2NR3R4, SO3R3, (CH2)nP(O)(OR )2, NR3SO2R4, aldehyde, nitrile, nitro, alkyl, T(CH2)mQR8, C(O)T(CH2)mQR8, NR8C(O)T(CH2)mQRπ, or T(CH2)mCO2R3 where n and m independently are 1 -6; T is O, S, NR3, N(O)R3, NR3R4W, or CR3R4; and Q is O, S, NR9,
N(O)R9 or NR9R10X;
R8, R9, R10 and Rπ are hydrogen, alkyl, or aryl;
X is a halogen; or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof.
35. A compound of Claim 1 wherein R1 is alkyl.
36. A compound of Claim 1 wherein R1 is isopropyl.
37. A compound of Claim 1 wherein R1 is cycloalkyl.
38. A compound of Claim 1 wherein R is cyclopentyl.
39. A compound of Claim 1 wherein R2 is hydroxy.
40. A compound of Claim 1 wherein R2 is alkyloxy.
41. A compound of Claim 1 wherein R is methoxy.
42. A compound of Claim 1 wherein R2 is NR3R4.
43. A compound of Claim 1 wherein A is CW3.
44. A compound of Claim 1 wherein W3 is piperidine.
45. A compound of Claim 1 wherein W is substituted piperidine.
46. A compound of Claim 1 wherein W is pyrolidine.
47. A compound of Claim 1 wherein W is substituted pyrolidine.
48. A compound of Claim 1 wherein W3 is piperazine.
49. A compound of Claim 1 wherein W3 is substituted piperazine
50. A compound of Claim 1 wherein W3 is hydrogen.
51. A compound of Claim 1 wherein W2 and W3 are hydrogen.
52. A compound of Claim 1 wherein R5 is hydrogen.
53. A compound of Claim 1 wherein R5 is alkyl.
54. A compound of Claim 1 wherein R6 is hydrogen.
55. A compound of Claim 1 wherein R is alkyl.
56. A compound of Claim 1 wherein W^, W2, and W^ are hydrogen.
57. A compound of Claim 1 wherein wherein R^ and R^ are hydrogen.
58. A compound of Claim 1 wherein wherein Wl, W2, and W^ are hydrogen, and
R1 is alkyl.
59. A compound of Claim 1 wherein wherein W^, W2, and W^ are hydrogen, and R! is cycloalkyl.
60. A compound of Claim 1 wherein wherein W-> is piperidine or substituted piperidine, and R! is alkyl or cycloalkyl.
61. A compound of Claim 1 wherein W^ is pyrrolidine or substituted pyrrolidine, and R! is alkyl or cycloalkyl.
62. A compound of Claim 1 wherein W^ is piperazine or substituted piperazine, and R! is alkyl or cycloalkyl.
63. A compound of Claim 1 wherein W^ is piperidine or substituted piperidine, R2 is alkyloxy, and R! is alkyl or cycloalkyl.
64. A compound of Claim 1 wherein wherein W^ is pyrrolidine or substituted pyrrolidine, R2 is alkyloxy, and Rl is alkyl or cycloalkyl.
65. A compound of Claim 1 wherein W^ is piperazine or substituted piperazine, R2 is alkyloxy, and R^ is alkyl or cycloalkyl.
66. A pharmaceutical formulation comprising a compound selected from Claims 1 -66 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
67. A method for controlling proliferative disorders in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
68. A method for controlling proliferative disorder according to Claim 67 wherein the disorder is selected from the group consisting of atherosclerosis, postsurgical vascular stenosis, and restenosis.
69. A method for controlling neurodegenerative disorders in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
70. A method of inhibiting a cyclin-dependent kinase comprising contacting the cyclin-dependent kinase with a compound selected from one of Claims 1-66.
71. A method of Claim 70 wherein said cyclin-dependent kinase is cdkl.
72. A method of Claim 70 wherein said cyclin-dependent kinase is cdk2.
73. A method of Claim 70 wherein said cyclin-dependent kinase is cdk4.
74. A method for controlling infections in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
75. A method for controlling cancer in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
76. A method for controlling autoimmune diseases in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
77. A method for controlling gout in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
78. A method for controlling kidney disease in mammals comprising administration to said mammal a therapeutically effective pharmaceutical formulation according to one of Claims 1-66.
79. A compound of Formula III
wherein
R1 is hydrogen, alkyl, alkyl substituted with at least one of amine, halogen, hydroxy, or alkoxy, cycloalkyl, or heterocycloalkyl;
R2 is OH, alkyloxy, aryloxy, or NR3R4;
R5 is hydrogen, or alkyl; R6 is hydrogen, alkyl, halogen, haloalkyl, alkynyl, alkenyl, COR3, CO2R3,
CONR3R4, SO2NR3R4, SO2R3, SO3R3, PO3R3, aldehyde, nitrile, nitro,
OR3, orNR3R4; and
X is oxygen or halogen or a pharmaceutically acceptable salt, ester, amide, or pro-drug thereof.
80. A compound of Claim 79 wherein R2 is alkyloxy, R^ is hydrogen or alkyl, R6 is hydrogen, and R° is oxygen or chlorine.
EP00976914A 1999-11-22 2000-11-03 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes Withdrawn EP1235815A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16684099P 1999-11-22 1999-11-22
US166840P 1999-11-22
PCT/US2000/030376 WO2001038315A1 (en) 1999-11-22 2000-11-03 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes

Publications (1)

Publication Number Publication Date
EP1235815A1 true EP1235815A1 (en) 2002-09-04

Family

ID=22604900

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976914A Withdrawn EP1235815A1 (en) 1999-11-22 2000-11-03 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes

Country Status (7)

Country Link
EP (1) EP1235815A1 (en)
JP (1) JP2003514901A (en)
AU (1) AU1462101A (en)
BR (1) BR0015718A (en)
CA (1) CA2386955A1 (en)
MX (1) MXPA02003140A (en)
WO (1) WO2001038315A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
FR2815032B1 (en) * 2000-10-10 2003-08-08 Pf Medicament NOVEL AMINOPHENYL PIPERAZINE OR AMINO PHENYL PIPERIDE DERIVATIVES PRENYL TRANSFERASE PROTEIN INHIBITORS AND PREPARATIONS THEREOF
US7119111B2 (en) * 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
EP1620105B1 (en) 2003-04-16 2007-01-10 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido¬3,4-d|pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatory conditions such as rheumatoid arthritis
JP2006523638A (en) * 2003-04-16 2006-10-19 エフ．ホフマン−ラ　ロシュ　アーゲー Quinazoline compounds
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006017844A1 (en) 2004-08-06 2006-02-16 Janssen Pharmaceutica, N.V. NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7906522B2 (en) 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
WO2007092839A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
AR060358A1 (en) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic QUINAZOLINS FOR THE INHIBITION OF PDK 1
WO2008050808A1 (en) * 2006-10-24 2008-05-02 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
JPWO2009084695A1 (en) 2007-12-28 2011-05-19 カルナバイオサイエンス株式会社 2-Aminoquinazoline derivatives
NZ586831A (en) 2008-01-28 2012-02-24 Janssen Pharmaceutica Nv 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
NZ586830A (en) 2008-01-29 2012-02-24 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
AU2009233951B2 (en) * 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
CA2748319A1 (en) * 2008-12-29 2010-07-08 Fovea Pharmaceuticals Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation
US20120041195A1 (en) 2009-02-13 2012-02-16 Fovea Pharmaceuticals Heterocyclic compounds
AR081960A1 (en) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa HETEROCICLICAL COMPOUNDS, ITS PREPARATION AND THERAPEUTIC APPLICATION
DK2872491T3 (en) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
ES2750236T3 (en) * 2013-12-09 2020-03-25 UCB Biopharma SRL Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
ES2705709T3 (en) 2014-12-24 2019-03-26 Gilead Sciences Inc Isoquinoline compounds for the treatment of HIV
TWI770552B (en) 2014-12-24 2022-07-11 美商基利科學股份有限公司 Quinazoline compounds
KR101985122B1 (en) 2014-12-24 2019-05-31 길리애드 사이언시즈, 인코포레이티드 Fused pyrimidine compounds for the treatment of hiv
AR112027A1 (en) * 2017-06-15 2019-09-11 Biocryst Pharm Inc ALK 2 KINASE INHIBITORS CONTAINING IMIDAZOLE
CN112661750B (en) * 2020-12-29 2022-10-21 西南大学 Ketene-bridged quinazolinone thiazole compound and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
CA1307786C (en) * 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
BR9807305A (en) * 1997-02-05 2000-05-02 Warner Lambert Co Pyrido [2,3-d] pyrimidines and 4-aminopyrimidines as inhibitors of cell proliferation.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0138315A1 *

Also Published As

Publication number Publication date
AU1462101A (en) 2001-06-04
JP2003514901A (en) 2003-04-22
WO2001038315A1 (en) 2001-05-31
BR0015718A (en) 2002-07-23
MXPA02003140A (en) 2002-09-30
CA2386955A1 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
EP1235815A1 (en) Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
CA2329703C (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US8309571B2 (en) Heterobicyclic compounds useful as kinase inhibitors
US7576091B2 (en) Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
EP0964864B1 (en) Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US7781583B2 (en) Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones
AU2007316417B2 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
JP6105578B2 (en) Heterocyclic protein kinase inhibitors
SK3542002A3 (en) Pteridinones as kinase inhibitors
US20090215805A1 (en) 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors
AU2006205710A1 (en) 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy
SK10772002A3 (en) Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
WO2003004488A1 (en) Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
CA2590294A1 (en) Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20040044012A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
SK12472002A3 (en) 5-Alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
MXPA02007221A (en) PYRIDO[2,3 d]PYRIMIDINE 2,7 DIAMINE KINASE INHIBITORS.
US6982260B1 (en) Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US7026313B2 (en) 2-thia-1,6,8-triaza-naphthalene-2,2-dioxides are kinase inhibitors
WO2012121168A1 (en) Kinase inhibitor
JP2008505950A (en) Novel 2,4-diaminothiazol-5-one derivative
EP1801112A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
Jain Design and synthesis of novel benzimidazoles and aminothiazoles as small molecule inhibitors of CDK5/p25

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020624

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WARNER-LAMBERT COMPANY LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WARNER-LAMBERT COMPANY LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070601